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44 Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, 
45 prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it 
46 remains unclear whether real-world CML management is consistent with these goals. We report 
47 results of UK TARGET CML, a retrospective observational study of 257 patients with chronic-
48 phase CML prescribed a first-line TKI between 2013 and 2017, most of whom received first-line 
49 imatinib (n=203). Although 44% of patients required ≥1 change of TKI, these real-world data 
50 revealed that molecular assessments were frequently missed, 23% of patients with ELN-defined 
51 treatment failure did not switch TKI and kinase domain mutation analysis was performed in only 
52 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR-
53 ABL1IS ≤0.1%) and deep molecular response (DMR; BCR-ABL1IS ≤0.01%) were observed in 
54 50% and 29%, respectively, of patients treated with first-line imatinib and 63% and 54% 
55 receiving a second-generation TKI first line. MMR and DMR were also observed in 77% and 
56 44% of evaluable patients with ≥13 months’ follow-up receiving a second-generation TKI 
57 second line. We found little evidence that cardiovascular risk factors were considered during TKI 
58 management. These findings highlight key areas for improvement in providing optimal care to 
59 patients with CML.
60
61 Keywords: tyrosine kinase inhibitor, chronic myeloid leukaemia, real-world study, molecular 
62 response, management 
































































64 Tyrosine kinase inhibitors (TKIs) have revolutionised outcomes for patients with chronic 
65 myeloid leukaemia in chronic phase (CML-CP), with survival rates approaching those of the 
66 general population (Bower et al, 2016; Hoglund et al, 2013; Sasaki et al, 2015). Consequently, 
67 key considerations for optimal patient care have evolved considerably. While the primary aim 
68 remains achievement of molecular response that minimises the risk of disease progression 
69 (Baccarani et al, 2013), increasingly, complications of the treatment need to be considered. It is 
70 therefore essential for physicians to understand the best use of the available ABL1-targeting 
71 TKIs (Baccarani et al, 2013). This is the principal purpose of the 2013 European LeukemiaNet 
72 (ELN) recommendations, which increased focus on molecular responses at 3, 6 and 12 months, 
73 with patients’ responses categorized as optimal, warning or failure (Baccarani et al, 2013). 
74 Patients experiencing failure are at particular risk of disease progression, and the guidelines 
75 recommend that such patients switch treatment and undergo assessment for BCR-ABL1 kinase 
76 domain mutations (Baccarani et al, 2013).
77
78 While the ELN 2013 guidelines state that patients must achieve a major molecular response 
79 (MMR; BCR-ABL1 ≤0.1% on the International Scale [IS]) by 12 months for their response to be 
80 considered optimal (Baccarani et al, 2013), deeper levels of response, including MR4 (BCR-
81 ABL1IS ≤0.01%) and MR4.5 (BCR-ABL1IS ≤0.0032%), are also recognized as important 
82 milestones (Cross et al, 2012; Etienne et al, 2014; Hehlmann et al, 2014). Some patients with a 
83 sustained deep molecular response (DMR; MR4 or better) may be eligible to attempt treatment-
84 free remission (TFR) (Hochhaus et al, 2017b; Mahon, 2017; NCCN, 2020; Rea et al, 2018). 
85 Clinical trials have demonstrated that patients are more likely to achieve optimal and deeper 































































86 responses to first-line therapy at key ELN milestones when second-generation (2G) TKIs are 
87 used rather than imatinib; however, achievement of responses in real-world practice is less well 
88 studied, particularly in the second-line setting (Cortes et al, 2018a; Cortes et al, 2016; Hochhaus 
89 et al, 2016). Achievement of ELN-defined responses and how ELN guidelines are implemented 
90 in real-world settings are infrequently explored.
91
92 An increased risk of cardiovascular (CV) adverse events (AEs) has been described in patients 
93 receiving 2G- or third-generation–TKIs compared with imatinib, especially in patients with pre-
94 existing CV risk factors (Chai-Adisaksopha et al, 2016; Cortes et al, 2018b; Cortes et al, 2016; 
95 Hochhaus et al, 2016; Lipton et al, 2016). Given the excellent long-term outcomes in CML, 
96 comorbidities are now a major consideration (Jabbour et al, 2014; Saussele et al, 2015). 
97 However, in UK routine clinical practice, it is unclear how physicians assess and manage CV 
98 risk factors or how CV risk factors affect TKI management.
99
100 UK TARGET CML (CAMN107CGB12) is a retrospective observational study of baseline 
101 assessment of patients with CML-CP, TKI treatment pathways, response monitoring patterns and 
102 response rates in routine UK National Health Service (NHS) clinical practice; we compared 




107 This retrospective noninterventional study was conducted at 21 UK NHS secondary and tertiary 
108 care centres. Data were collected from paper and electronic records. Inclusion criteria included 































































109 CML-CP diagnosis at start of first-line TKI, age ≥18 years and ≥6 months of follow-up from 
110 date of first TKI (between January 2013 and April 2017). Patients prescribed first TKI in a 
111 clinical trial and patients in accelerated phase (AP) or blast phase (BP) before initiation of first 
112 TKI were excluded.
113
114 Objectives were to describe TKI treatment pathways in the UK, patient characteristics, practices 
115 for assessing and managing CV risk factors before TKI treatment, responses to first- and second-
116 line TKI therapy at ELN time points, recorded reasons for stopping/changing TKIs, adherence to 
117 ELN 2013 recommendations and disease progression frequency and management. AE data were 
118 not collected.
119
120 Data were analysed using descriptive statistics, with a cutoff date of June 6, 2018, using 
121 Microsoft Excel and STATA (version 13; StataCorp LLC, College Station, TX, USA). A study 
122 size of 200-250 patients in approximately 20 centres (maximum of 40 patients/centre) was 
123 expected to give a representative sample of patients in the UK and provide reliable quantitative 
124 and qualitative variables.
125
126 For comparison with ELN, where data were available, responses were categorised as optimal, 
127 warning or failure according to ELN 2013 recommendations (Baccarani et al, 2013).  If BCR-
128 ABL1 transcript levels were not available on the IS, unconverted BCR-ABL1/ABL1 percentages 
129 were used to reflect real-world practices at that centre (all centres used ABL1 as a reference 
130 gene). Two of 14 centres (14%) reported on the IS in 2013; increasing to 17/21 (81%) in 2017. 
131
































































133 Patient demographics and baseline characteristics
134 Two-hundred-fifty-seven patients (186 from 14 tertiary centres and 71 from 7 general hospitals) 
135 were enrolled between November 2015 and September 2017. Median follow-up by the data 
136 cutoff was 32.9 months (range, 12.6-58.6). Baseline characteristics are shown in Table I. 
137 Clinical characteristics (other than white blood cell counts) and risk scores at diagnosis were not 
138 well documented.
139
140 The first-line TKI was imatinib in the majority of patients (79%); reasons for first-line TKI 
141 choice were recorded for <50% of patients: clinician preference, “standard first-line choice” and 
142 “good results expected” were the most frequently cited reasons (Supplementary Table I). First-
143 line imatinib and 2G-TKIs were prescribed to 31/42 (74%) and 11/42 (26%) patients with high 
144 Sokal scores, respectively, and 23/34 (68%) and 11/34 (32%) with high European Treatment and 
145 Outcomes Study (EUTOS) scores. Patients receiving a first-line 2G-TKI were younger (median, 
146 46 years [95% CI, 41-53 years] than those receiving first-line imatinib (median, 55 years [95% 
147 CI, 52-59 years]; Mann-Whitney U test, P = 0.0128). 
148
149 CV risk factors and other documented comorbidities at baseline
150 Among all patients, 149 (58%) had ≥1 recorded comorbidity at baseline (Table I). Seventy-four 
151 patients (36%) receiving imatinib had CV comorbidities at baseline vs 7 (13%) receiving a 2G-
152 TKI (Table II). Only 74 patients (29%) had baseline blood pressure documented; 33 (45%) had 
153 stage ≥2 hypertension (Supplementary Table II) (Whelton et al, 2018).
154































































155 Exact levels of baseline blood glucose were documented in 58 patients (23%); documentation 
156 occurred more often in patients treated with first-line 2G-TKI (20/54 [37%]) vs imatinib (38/203 
157 [19%]). Baseline low-density lipoprotein and total cholesterol levels were recorded in 23 (9%) 
158 and 40 (16%) patients. CV risk assessment tool use was documented for 10 patients (4%), with 
159 the validated QRISK2 tool used in 3 (1%).
160
161 Response monitoring practices
162 Within 12 months of starting first-line TKI, 250 patients (97%) had ≥1 real-time quantitative 
163 polymerase chain reaction (RQ-PCR) assessment and 221 patients (86%) had ≥3 RQ-PCR 
164 assessments. Two-hundred-four (79%), 177 (69%), and 162 (63%) patients had assessments at 
165 the 3-, 6-, or 12-month ELN milestones (regardless of TKI line), respectively. Cytogenetic 
166 testing (chromosome banding analysis or fluorescence in situ hybridization) was conducted less 
167 frequently. Frequency of assessments at ELN milestones on first and second TKI are described 
168 in Table III.
169
170 First-line TKI therapy
171 Median follow-up duration on first-line TKI and molecular responses to first-line TKI therapy 
172 are shown in Table IV. Time to discontinuation of first TKI for patients on imatinib vs 2G-TKI 
173 is shown in Fig 1. For patients receiving imatinib or nilotinib, respective median starting doses 
174 were 400 or 600 mg/day; 24/203 (12%) and 8/50 (16%) had dose reductions, while 14% and 
175 12% had dose interruptions.
176































































177 Quantifiable molecular or cytogenetic assessments were performed at ≥1 ELN milestone during 
178 first-line TKI in 223 patients (87%) (Fig 2). Forty-eight patients had ≥1 failure; 11 (23%) 
179 remained on first-line TKI (median follow-up, 13.8 months [interquartile range (IQR), 12.8-
180 25.9]), and 37 (77%) switched TKIs (median follow-up, 25.1 months [IQR, 14.3-32.6]).
181
182 Second-line TKI therapy
183 At least one TKI switch occurred in 113 patients (44%); 54 (21%) switched more than once. 
184 Reasons for the first switch were resistance in 73 (65%), intolerance in 38 (34%) and other 
185 reasons in 2 (2%) (Supplementary Table III). Thirteen patients (12%) switched to imatinib, 68 
186 (60%) to nilotinib, 20 (18%) to dasatinib, 11 (10%) to bosutinib and one (1%) to ponatinib 
187 (Supplementary Table IV). For patients receiving second-line imatinib, nilotinib, dasatinib and 
188 bosutinib, median starting doses (range) were 400 (200-400), 600 (200-800), 100 (50-100) and 
189 300 (100-500) mg/day, respectively.
190
191 Median follow-up duration after switching to second TKI was 23.7 months (range, 1.2-54.1) 
192 (Table V). MMR at any time and DMR at any time were observed in 37/51 (73%) and 21/51 
193 (41%) patients with ≥13 months’ follow-up on second line. Molecular responses to second-line 
194 TKI for all patients regardless of follow-up duration are shown in Supplementary Table V.
195
196 Of 113 patients who switched TKI at least once, 18 (16%) had failure on second-line TKI 
197 (Supplementary Fig 1); 7 (39%) remained on that TKI (median follow-up, 24.3 months [IQR, 
198 11.6-31.0]), while 11 (61%) switched again (median follow-up, 27.5 months [IQR, 16.4-33.8]).
199































































200 Kinase domain mutation analysis
201 BCR-ABL1 kinase domain mutational analysis was performed prior to the first switch in 24 
202 patients (21%), including 20 (27%) who switched due to resistance and 4 (10%) who switched 
203 due to intolerance or other reasons. Clinically actionable mutations were identified in 6 patients 
204 (Supplementary Table VI).
205
206 Overall TKI pathways
207 Among all patients, 144 (56%) received only a first-line TKI, and 59 (23%), 35 (14%), 16 (6%) 
208 and 3 (1%) received 2, 3, 4 and 5 TKIs, respectively; sequences of TKI received are described in 
209 Supplementary Table IV. Eleven patients received the same TKI in multiple lines of therapy.
210
211 Disease progression
212 Ten patients progressed to AP and/or BP, and 15 patients died (10 in CP and 5 after progression). 
213 Survival outcomes and treatments to manage progression are summarized in Fig 3.
214
215 Discussion
216 The management of CML has undergone dramatic changes; however, it remains unclear whether 
217 real-world practice in the UK has evolved with these developments. We conducted the UK 
218 TARGET CML study to assess this question, with a particular focus on (1) TKI treatment 
219 pathways, (2) implementation of ELN recommendations for molecular-based patient 
220 management, (3) attainment of DMR with first- and second-line TKI in real-world practice and 
221 (4) assessment of baseline CV risk factors.
222































































223 Despite relatively short median follow-up (<33 months), almost half of patients switched from 
224 first-line TKI, most often due to resistance (65%). In addition, 21% of patients received ≥3 lines 
225 of TKIs. This frequency of TKI switching was somewhat higher than that observed in 
226 prospective clinical trials, such as the pivotal trial of frontline imatinib (International 
227 Randomized Study of Interferon and STI571 [IRIS]), which reported that 34% of patients 
228 discontinued treatment after 6 years of follow-up, although no other alternative TKI was 
229 available at the time of IRIS recruitment (Hochhaus et al, 2009). In IRIS long-term follow-up 
230 (median, 10.9 years), imatinib discontinuation was most frequently attributed to unsatisfactory 
231 therapeutic effect (15.9%), withdrawal of consent (10.3%), or AEs (6.9%) (Hochhaus et al, 
232 2017a). Similarly, in the frontline trial of nilotinib (Evaluating Nilotinib Efficacy and Safety in 
233 Clinical Trials–Newly Diagnosed Patients [ENESTnd]), treatment discontinuations were most 
234 frequently due to suboptimal response/treatment failure or AEs/abnormal laboratory values (12% 
235 each by the 5-year data cutoff among patients allocated to nilotinib 300 mg twice daily) 
236 (Hochhaus et al, 2016). We found that in real-world practice, approximately half of patients 
237 required a change of TKI, highlighting the importance of optimal monitoring of molecular 
238 responses and treatment-related side effects to ensure proper use of TKIs and timely switching. 
239 These data also demonstrated the ongoing challenge of establishing a satisfactory, long-term 
240 treatment, with multiple TKI switches being common.
241
242 Although 58% of patients had a recorded comorbidity, patients generally had poorly documented 
243 baseline clinical characteristics and prognostic scores. Demographic and baseline characteristics 
244 were not dissimilar from those of other real-world cohorts (Goldberg et al, 2017; Hoglund et al, 
245 2013; Nesr et al, 2018), although prognostic scores were better documented (98%) in the 































































246 Swedish CML registry (Hoglund et al, 2013). CV events have been reported to be increased with 
247 2G-TKIs (Chai-Adisaksopha et al, 2016; Cortes et al, 2016; Hochhaus et al, 2016), and CV risk 
248 factors should therefore be carefully considered when choosing a TKI. Even with first-line 
249 imatinib, it is important to assess CV risk given that approximately half of patients will require a 
250 switch to a 2G-TKI at some point. Although late complications with 2G-TKIs were not fully 
251 understood or evaluable at the time of ELN 2013, the guidelines nevertheless recommended 
252 continued clinical monitoring of all patients. Several CV risk factors were very poorly 
253 documented in our cohort, and any use of validated CV risk tools, such as QRISK2, was rarely 
254 documented. Baseline blood pressure was documented in fewer than one-third of patients; when 
255 baseline blood pressure was recorded, it was often elevated, with 3 patients in hypertensive 
256 crisis, illustrating the importance of documenting this parameter so that hypertension can be 
257 managed appropriately. However, some evidence was observed that CV comorbidities at 
258 baseline played a role in first-line TKI choice, with patients appearing more likely to receive 
259 first-line imatinib if a CV comorbidity was documented.
260
261 Currently, the UK National Institute for Health and Care Excellence (NICE) recommends NHS 
262 funding in England of imatinib, nilotinib or dasatinib in the first line and nilotinib, dasatinib, 
263 bosutinib or ponatinib in later lines (NICE, 2018). In this cohort, first-line treatment was mostly 
264 imatinib or nilotinib (<2% received first-line dasatinib), and second-line treatment was mostly 
265 nilotinib, reflecting NICE recommendations at the start of treatment for these patients (dasatinib 
266 was not routinely available). Patients were more likely to receive first-line 2G-TKIs than 
267 imatinib if they were younger and had no documented comorbidities. Overall, prognostic scores 
268 were poorly documented despite strong evidence that these risk scores remain highly predictive 































































269 of disease response in the TKI era (Hochhaus et al, 2016). We did not find evidence that 
270 prognostic scores played a major role in first-line TKI choice, with a majority of patients 
271 identified as high risk by Sokal, EUTOS or Hasford criteria being treated with imatinib. Overall, 
272 4% of patients progressed to AP and/or BP, corresponding well with the results of the Swedish 
273 CML registry (3% by 12 months) (Hoglund et al, 2013).
274
275 One key finding of this study is that ELN 2013 monitoring recommendations were not 
276 consistently implemented. Patients frequently did not have assessments at recommended time 
277 points. This finding is consistent with those from the SIMPLICITY study, which reported that 
278 monitoring was conducted less frequently than recommended, although with higher frequency in 
279 Europe than the United States (Goldberg et al, 2017). This finding is important because a 
280 previous study showed that patients without frequent molecular monitoring were at higher risk of 
281 disease progression (Goldberg et al, 2013). In addition, frequent molecular monitoring (3-4 times 
282 per year) was associated with greater TKI treatment adherence in patients with CML (Guerin et 
283 al, 2014).
284
285 Overall, in our study, 86% of patients had ≥3 molecular response tests during their first year of 
286 TKI treatment, while SIMPLICITY reported 46% for Europe (Goldberg et al, 2017), a finding 
287 that potentially reflects UK-specific practice or changes in practice over time (UK patients who 
288 were first treated in 2013-2017 were compared with SIMPLICITY patients first treated in 2010-
289 2015). Furthermore, our UK study observed a relatively high level of testing for early molecular 
290 response (EMR) at 3 months (81%) compared with SIMPLICITY (32%), indicating rapid 
291 adoption of molecular monitoring at early milestones in the UK (Goldberg et al, 2017).
































































293 However, despite a generous 1-month window applied around ELN milestones, a large 
294 proportion of patients (≈20%-30%) were still without evaluable molecular or cytogenetic test 
295 results at any given time point during their first year of TKI treatment. Moreover, 13% of 
296 patients had no evaluable molecular or cytogenetic result at any ELN milestone during the first 
297 year of TKI treatment.
298
299 ELN recommended that a patient with ELN-defined failure should have their TKI switched to 
300 reduce the risk of progression. Nevertheless, a number of patients in TARGET remained on first-
301 line TKI despite ELN-defined treatment failure.
302
303 Strikingly, BCR-ABL1 kinase domain mutational analyses, recommended by ELN in warning or 
304 failure, were infrequently performed, even in patients with documented resistance, despite the 
305 known importance of mutation status for subsequent TKI selection. Patients did not always have 
306 recommended baseline assessments such as qualitative PCR despite its importance in 
307 determining BCR-ABL1 transcript type, which can affect future molecular monitoring, especially 
308 at the low levels before consideration for TFR. Furthermore, although bone marrow and 
309 cytogenetic analysis still have an essential role in assessment of patients at baseline, many 
310 patients were managed without bone marrow or cytogenetic analysis. Bone marrow evaluation 
311 before TKI switching was infrequently performed, which may reflect the current use of PCR 
312 thresholds for interpretation of resistance.
313































































314 Clinical trials have shown that 2G-TKIs lead to improved rates of molecular responses compared 
315 with imatinib (Cortes et al, 2018a; Cortes et al, 2016; Hochhaus et al, 2016). In this cohort, 
316 observed rates of EMR and MMR at ELN milestones and DMR at any time during first-line TKI 
317 were higher with 2G-TKIs than with imatinib, confirming the results in this real-world setting. 
318 While EMR and MMR were defined as optimal responses in ELN 2013 (Baccarani et al, 2013), 
319 treatment goals are evolving to include deeper responses and TFR (Hochhaus et al, 2017b; 
320 NCCN, 2020; Rea et al, 2018). Studies have shown that deeper molecular responses were 
321 associated with improved outcomes compared with complete cytogenetic response (Etienne et al, 
322 2014; Hehlmann et al, 2014), and a sustained DMR is a prerequisite for attempting TFR in both 
323 clinical practice guidelines (Hochhaus et al, 2017b; NCCN, 2020; Rea et al, 2018) and clinical 
324 trials (Mahon et al, 2018; Ross et al, 2018). Clinical studies have demonstrated that 2G-TKIs can 
325 also lead to improved rates of DMR in the second line (Hughes et al, 2017). Results from our 
326 study showed that patients switching from first-line treatment may achieve not only optimal 
327 responses but also deeper responses, including patients with prior resistance or ELN-defined 
328 failure.
329
330 A criticism of observational studies is the increased risk of selection bias and confounding, 
331 precluding the robust analysis and conclusions provided by randomized controlled trials. 
332 However, real-world evidence plays an important role in allowing physicians to reflect on 
333 current practice. Our study demonstrated that almost half of patients required TKI switch in real-
334 world practice and that optimal and deep responses can be achieved by patients who switch. 
335 However, inadequate CV risk assessment, response monitoring, and mutational analysis 
336 increased the risk of inappropriate patient management and, as such, the findings of this study 































































337 highlighted key areas for improvement in care for patients with CML. Further consideration for 
338 improving implementation of guidelines in real-world clinical practice, including very recent 
339 updates to the ELN recommendations (Hochhaus et al 2020), is warranted.
340
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Male 144 (56) 119 (59) 25 (46) 24 (48)
Female 113 (44) 84 (41) 29 (54) 26 (52)














Time from CML diagnosis to start of first TKI, 
median (IQR), days
7.0 (1.0-20.0) 8.0 (2.0-20.3) 6.0 (1.0-11.0) 6.0 (1.0-11.0)
Assessments prior to first-line TKI, n (%)
RQ-PCR 169 (66) 140 (69) 29 (54) 26 (52)
Qualitative PCR (b2a2, b3a2, other) 140 (54) 107 (53) 33 (61) 30 (60)
CBA 180 (70) 146 (72) 34 (63) 31 (62)
FISH 155 (60) 117 (58) 38 (70) 34 (68)
CBA or FISH (bone marrow) 154 (60) 119 (59) 35 (65) 32 (64)
CBA or FISH (peripheral blood) 54 (21) 45 (22) 9 (17) 9 (18)
Both CBA/FISH and RQ-PCR 139 (54) 117 (58) 22 (41) 20 (40)
Treatment for CML prior to first-line TKI, n (%)
Yes 126 (49) 97 (48) 29 (54) 26 (52)
Prior treatmenta,b
Hydroxycarbamide 116 (92) 89 (92) 27 (93) 24 (92)
Leukapheresis 2 (2) 2 (2) 0 0
Anagrelide 1 (1) 1 (1) 0 0
Interferon 1 (1) 1 (1) 0 0
Aspirin 1 (1) 0 1 (3) 1 (4)
No 128 (50) 104 (51) 24 (44) 23 (46)
Unknown 3 (1) 2 (1) 1 (2) 1 (2)
Ph chromosome at baseline
Yes 212 (82) 175 (86) 37 (69) 35 (70)
No 3 (1) 1 (<1) 2 (4) 2 (4)
Unknown 42 (16) 27 (13) 15 (28) 13 (26)
Clinical characteristics








Unknown, n (%)c 4 (2) 1 (<1) 3 (6) 2 (4)








Unknown, n (%)c 14 (5) 11 (5) 3 (6) 2 (4)
Basophils, median (IQR), % 3.9 (2.0-7.0) 3.3 (2.0-6.0) 5.0 (2.3-8.0) 4.0 (2.3-8.3)
Unknown, n (%)c  59 (23) 46 (23) 13 (24) 13 (26)
Eosinophils, median (IQR), % 2.0 (1.1-3.7) 2.0 (1.1-3.5) 2.0 (1.3-3.7) 2.0 (1.3-3.0)
Unknown, n (%)c 58 (23) 45 (22) 13 (24) 13 (26)
Blasts, median (IQR) (%) 2.0 (1.0-4.8) 2.0 (1.0-3.4) 3.0 (1.6-8.4) 3.0 (1.5-6.0)
Unknown, n (%)c 101 (39) 77 (38) 24 (44) 23 (46)
Spleen size below costal margin, median (IQR), 
cmd
1.3 (0.0-10.1) 1.0 (0.0-10.1) 4.0 (0.0-10.3) 2.0 (0.0-10.0)
Unknown, n (%)c 85 (33) 67 (33) 18 (33) 17 (34)
Sokal risk score, n (%)e
Low risk 52 (20) 43 (21) 9 (17) 8 (16)
Intermediate risk 54 (21) 41 (20) 13 (24) 13 (26)
High risk 42 (16) 31 (15) 11 (20) 9 (18)































































No score recorded and required components not 
all recorded
109 (42) 88 (43) 21 (39) 20 (40)
EUTOS score, n (%)f
Low risk 110 (43) 90 (44) 20 (37) 19 (38)
High risk 34 (13) 23 (11) 11 (20) 9 (18)
No score recorded and required components not 
all recordedg
113 (44) 90 (44) 23 (43) 22 (44)
Hasford score, n (%)h
Low risk 25 (10) 19 (9) 6 (11) 5 (10)
Intermediate risk 35 (14) 32 (16) 3 (6) 3 (6)
High risk 19 (7) 13 (6) 6 (11) 4 (8)
No score recorded and required components not 
all recorded
178 (69) 139 (68) 39 (72) 38 (76)
Comorbidities, n (%)
None recorded 108 (42) 80 (39) 28 (52) 26 (52)
≥1 recordedi,j 149 (58) 123 (61) 26 (48) 24 (48)
CV comorbidities 81 (32) 74 (36) 7 (13) 6 (12)
Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Respiratory disease 20 (8) 17 (8) 3 (6) 3 (6)
Renal disease 16 (6) 14 (7) 2 (4) 2 (4)
Non-haematological cancer 9 (4) 8 (4) 1 (2) 1 (2)
Hepatic disease 4 (2) 3 (1) 1 (2) 1 (2)
Other 86 (33) 70 (34) 16 (30) 15 (30)
549 2G-TKI, second-generation tyrosine kinase inhibitor; CBA, chromosome banding analysis; CML, chronic myeloid 
550 leukaemia; CV, cardiovascular; EUTOS, European Treatment and Outcomes Study; FISH, fluorescence in situ 
551 hybridization; IQR, interquartile range; Ph, Philadelphia chromosome; RQ-PCR, real-time quantitative polymerase 
552 chain reaction; WBC, white blood cell.
553 a Patients may have received multiple prior treatments.
554 b Proportion of patients with each prior treatment was calculated out of the total number of patients who received 
555 prior treatment.
556 c Proportion of patients with unknown clinical characteristics was calculated out of the total number of patients in 
557 each column.
558 d Spleens reported to be “normal” or “nonpalpable” were considered to be 0 cm below the costal margin.
559 e Among 148 patients who received any first-line TKI and had an available Sokal risk score at diagnosis, the score 
560 was documented for 96 (65%) and not documented and instead calculated during this analysis for 52 (35%).
561 f Among 144 patients who received any first-line TKI and had an available EUTOS risk score at diagnosis, the score 
562 was documented for 36 (25%) and not documented and instead calculated during this analysis for 108 (75%).
563 g Includes patients who had a risk category recorded but no score recorded.
564 h Hasford scores were not collected in case report forms and were calculated if required data were available.
565 i Patients may have had multiple comorbidities.
566 j Proportion of patients with each comorbidity was calculated out of the total number of patients in each column.
567
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Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Smoking
Documenteda 174 (68) 140 (69) 34 (63) 32 (64)
Current smoker 38 (22) 35 (25) 3 (9) 3 (9)
Ex-smoker 46 (26) 39 (28) 7 (21) 6 (19)
Never smoked 88 (51) 65 (46) 23 (68) 22 (69)
Unclear 2 (1)b 1 (1)b 1 (3)b 1 (3)b
BMI >30 documented 16 (6) 14 (7) 2 (4) 2 (4)
CV comorbidities
None recorded 176 (68) 129 (64) 47 (87) 44 (88)
≥1 recordedc,d 81 (32) 74 (36) 7 (13) 6 (12)
Hypertension 58 (23) 52 (26) 6 (11) 5 (10)
Hyperlipidaemia 28 (11) 26 (13) 2 (4) 2 (4)
Coronary artery disease 14 (5) 12 (6) 2 (4) 2 (4)
Myocardial infarction 11 (4) 10 (5) 1 (2) 1 (2)
Coronary artery bypass graft 9 (4) 8 (4) 1 (2) 1 (2)
Arrhythmias 8 (3) 7 (3) 1 (2) 1 (2)
Cerebrovascular accident 4 (2) 4 (2) 0 0
Transient ischemic attack 4 (2) 3 (1) 1 (2) 1 (2)
Congestive heart failure 3 (1) 2 (1) 1 (2) 1 (2)
Unstable angina 2 (1) 2 (1) 0 0
Percutaneous coronary 
intervention
2 (1) 2 (1) 0 0
Peripheral vascular disease 2 (1) 2 (1) 0 0
History of CV disease
Not documented 101 (39) 80 (39) 21 (39) 20 (40)
Documentation unknowne 1 (<1) 1 (<1) 0 0
Documentedf 155 (60) 122 (60) 33 (61) 30 (60)
No history 26 (17) 23 (19) 3 (9) 3 (10)
Details of history not 
provided
104 (67) 76 (62) 28 (85) 25 (83)
Details of history provided 25 (16) 23 (19) 2 (6) 2 (7)
Family history of CV disease
Not documented 159 (62) 128 (63) 31 (57) 29 (58)
Documentation unknowne 1 (<1) 1 (<1) 0 0
Documented 97 (38) 74 (36) 23 (43) 21 (42)
570 2G-TKI, second-generation tyrosine kinase inhibitor; BMI, body mass index; CV, cardiovascular.
571 a Proportion of patients in each smoking category was calculated based on the number of patients with documented 
572 smoking status.
573 b Two patients were recorded as “does not smoke”; it was unclear whether they were ex-smokers or never smoked.
574 c Patients could be listed as having >1 CV comorbidity.
575 d Proportion of patients with CV comorbidities was calculated based on total number of patients in each column.
576 e One patient was transferred from another hospital prior to TKI treatment; it was unclear if this patient’s personal or 
577 family history of vascular disease had been documented prior to TKI treatment.
578 f Proportion of patients within each category was calculated based on the number of patients who had documented 
579 CV disease history.
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581 Table III. Frequency of molecular and cytogenetic assessments at ELN milestones for patients on 















3 monthsa 180/223 (81) 143/173 (83) 37/50 (74) 35/47 (74)
6 monthsb 141/199 (71) 105/154 (68) 36/45 (80) 34/42 (81)
12 monthsc 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
CBA/FISH
3 monthsa 15/223 (7) 15/173 (9) 0/50 (0) 0/47 (0)
6 monthsb 9/199 (5) 8/154 (5) 1/45 (2) 1/42 (2)
12 monthsc 2/170 (1) 2/132 (2) 0/38 (0) 0/35 (0)
CBA/FISH and/or RQ-PCR
3 monthsa 186/223 (83) 148/173 (86) 38/50 (76) 36/47 (77)
6 monthsb 151/199 (76) 114/154 (74) 37/45 (82) 35/42 (83)
12 monthsc 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
Second TKI
RQ-PCR
3 monthsa 63/82 (77) 8/10 (80) 55/72 (76) 43/54 (80)
6 monthsb 44/66 (67) 4/8 (50) 40/58 (69) 31/46 (67)
12 monthsc 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
CBA or FISH
3 monthsa 12/82 (15) 2/10 (20) 10/72 (14) 9/54 (17)
6 monthsb 4/66 (6) 0/8 (0) 4/58 (7) 4/46 (9)
12 monthsc 1/52 (2) 0/8 (0) 1/44 (2) 1/39 (3)
CBA/FISH and/or RQ-PCR
3 monthsa 65/82 (79) 8/10 (80) 57/72 (79) 45/54 (83)
6 monthsb 45/66 (68) 4/8 (50) 41/58 (71) 32/46 (70)
12 monthsc 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
≥1 assessment at an ELN milestone (first- or 
second-line TKI)a
239/257 (93) 189/203 (93) 50/54 (93) 48/50 (96)
583 CBA, chromosome banding analysis; ELN, European LeukemiaNet; FISH, fluorescence in situ hybridization; RQ-
584 PCR, real-time quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.
585 a Denominator included patients with ≥4 months’ follow-up on that TKI.
586 b Denominator included patients with ≥7 months’ follow-up on that TKI.
587 c Denominator included patients with ≥13 months’ follow-up on that TKI.
588































































589 Table IV. Summary of molecular responses to first-line TKI therapya









































EMR at 3 months 
















MMR by 12 
months (±1 
month), n (%)
84 (41) 28 (52) 112 (44) 71 (35) 26 (48) 25 (50) 97 (38)
MMR at any 
time, n (%)
156 
(77) 42 (78) 198 (77) 102 (50) 34 (63) 32 (64) 136 (53)
DMR at any 
time, n (%) 95 (47) 35 (65) 130 (51) 58 (29) 29 (54) 27 (54) 87 (34)
590 2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular 
591 response; IS, International Scale; MMR, major molecular response.
592 a Patients could appear in multiple molecular response categories. Molecular responses were assessed as EMR 
593 (BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any time and DMR (BCR-
594 ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, a window of ±1 month 
595 was applied to ELN-defined time points; if multiple assessments were available within the window, the one closest 
596 to the time point was used.
597 b Fifty patients received first-line nilotinib, and 4 received first-line dasatinib.
598 c The columns for overall response reported the duration of follow-up for all TKI therapies, including later-line TKIs 
599 in patients who switched from their first-line TKI (from start of first-line TKI to most recent data collection, akin to 
600 an intention-to-treat analysis). The columns for first-line TKI therapy reported the duration of follow-up for only 
601 first-line TKI therapy (from start of first-line TKI to most recent data collection or death in patients who continued 



































































606 Table V. Summary of molecular responses after switching to second-line TKI therapya






















































EMR at 3 months 
(±1 month) on 






59/70 (84) 10/10 (100) 49/60 (82) 38/45 (84) 39/47 (83) 20/23 (87)
MMR by 12 
months (±1 
month) on second 
TKI, n (%)g
30/50 (60) 4/7 (57) 26/43 (60) 24/38 (63) 21/35 (60) 9/15 (60)
MMR at any time 
on second TKI, n 
(%)g
37/51 (73) 4/8 (50) 33/43 (77) 29/38 (76) 27/36 (75) 10/15 (67)
DMR at any time 
on second TKI, n 
(%)g
21/51 (41) 2/8 (25) 19/43 (44) 17/38 (45) 15/36 (42) 6/15 (40)
607 2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular 
608 response; IS, International Scale; MMR, major molecular response.
609 a Patients could appear in multiple molecular response categories. Molecular responses after switch to second TKI 
610 were assessed as EMR (BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any 
611 time and DMR (BCR-ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, 
612 a window of ±1 month was applied to ELN-defined time points; if multiple assessments were available within the 
613 window, the one closest to the time point was used.
614 b Switched to 2G-TKI (n=68 nilotinib, n=20 dasatinib, n=11 bosutinib, n=1 ponatinib).
615 c Switched for intolerance (n=38) or switched for another reason (n=2).
616 d Duration from start of second-line TKI to last data collection or death (included patients with ≥1 switch).
617 e Duration from start of second-line TKI to last data collection, date of switch to a third-line TKI, or death.
618 f EMR defined as BCR-ABL1IS ≤10% at 3 months (±1 month); only those patients with BCR-ABL1 available at 3 
619 months were included.
620 g MMR (≤0.1% BCR-ABL1); DMR (≤0.01% BCR-ABL1); only those patients with ≥13 months’ follow-up were 
621 included.































































622 Fig 1. Kaplan-Meier curve: time to discontinuation of first-line TKI
623
624
625 Patients who had not switched from first TKI at point of data collection were censored at date of 
626 data collection or death. Months on first TKI were unknown for 10 patients on imatinib. TKI, 
627 tyrosine kinase inhibitor.
628































































630 Fig 2. TKI treatment pathways and molecular responses for patients with ELN optimal, 
631 warning (at single vs multiple ELN milestones) or failure responses while on first-line TKI
632
633
634 a To account for variations in real-world appointment scheduling, a window of ±1 month was applied to ELN-
635 defined time points (3, 6 and 12 months). In patients with multiple test results available, any patient with a failure 
636 response to first-line TKI at an ELN milestone (regardless of other responses achieved at earlier milestones) was 
637 classified as having a failure response. Patients in the optimal category had only optimal responses at an ELN 
638 milestone (3, 6 or 12 months) with either molecular or cytogenetic assessment (where a molecular test was not 
639 available). Patients in the warning category had a warning at any milestone with either assessment but had no failure 
640 at any milestone with either assessment. Patients without assessments at any ELN milestone could not be 
641 categorized. Thirty-four patients had no evaluable test at any ELN milestone by either molecular or cytogenetic test.
642 b Response may have been observed at any time. Duration of follow up varied; patient may have had ≥1 subsequent 
643 TKI switch. Forty-eight patients had ≥1 failure; 11 (23%) remained on first-line TKI (median follow-up, 13.8 
644 months [IQR, 12.8-25.9 months]), and 37 (77%) switched TKIs (median follow-up, 25.1 months [IQR, 14.3-32.6 
645 months]). Of those who switched, 22 had their first failure at 6 months (BCR-ABL1IS range, 10.1%-60.1%; 2 patients 
646 had a failure according to FISH), and 15 had their first failure at 12 months (BCR-ABL1IS range, 1.2%-12.7%). 
647 Among these patients with a failure who switched TKIs, 17 (46%) and 10 (27%) achieved MMR and DMR at any 
648 time, respectively, vs 4 (36%) and 0 patients who did not switch TKIs. Of 81 patients with warning but no failure, 
649 52 (64%) remained on first-line TKI (median follow-up 28.4 months [IQR, 13.7-40.4 months]), and 29 (36%) 
650 switched TKIs (median follow-up 30.9 months [IQR, 20.3-38.3 months]). Of those who switched TKIs, 19/29 had 
651 ≥1 additional RQ-PCR assessment between the initial warning and TKI switch. Of 34 patients without any 
652 quantifiable assessment at any ELN milestone, 27 (79%) switched TKIs. 
653 c Of 48 patients with ELN-defined failure responses, 39 were treated with imatinib as first-line therapy and 9 with a 
654 2G-TKI; 38 patients (79%) also had an ELN-defined warning at a prior ELN time point (with either a molecular or 
655 cytogenetic test).
656 DMR, deep molecular response; ELN, European LeukemiaNet; EMR, early molecular response; FISH, fluorescence 
657 in situ hybridization; IQR, interquartile range; IS, International Scale; MMR, major molecular response; RQ-PCR, 
658 real-time quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.































































659 Fig 3. Disease progressiona
660
661
662 a Eight patients (7 on imatinib, 1 on a second-generation TKI) progressed to accelerated phase (AP) during the course 
663 of the study. The median time to progression was 16.5 months (range, 2.1-31.1; IQR, 7.5-26.4; time to progression 
664 was unknown for one patient on first-line imatinib). Three patients had a prior warning response at an ELN milestone 
665 (all 3 patients received imatinib as first TKI), and 3 patients had a failure response at an ELN milestone (2 patients 
666 received imatinib first line and 1 patient received nilotinib). The other 2 patients who progressed to AP had no prior 
667 evaluable response at an ELN milestone (both patients received first-line imatinib). Treatments for progression to 
668 AP were TKIs in 3 patients, chemotherapy in 4 patients and allogenic haematopoietic stem cell transplant (HSCT) in 
669 5 patients. Six patients progressed to BP (all received first-line imatinib), including 4 who were previously recorded 
670 as progressing to AP. Median time from start of first-line TKI to progression to BP was 22.7 months (range 1.2- 32.1; 
671 IQR, 17.2-30.1). Treatments for progression to BP were TKIs in 4 patients, chemotherapy in 4 patients, allogenic HSCT 
672 in 2 patients and haploidentical allogenic HSCT in one patient. Among 4 patients who progressed to AP only, 2 
673 received 1 TKI prior to progression, 1 received 3 TKIs prior to progression, and 1 had an unknown date of disease 
674 progression. Among 4 patients who progressed to AP and BP, 2 each received 1 or 2 TKIs prior to their earliest 
675 progression, respectively. Among 2 patients who progressed to BP only, 1 each received 1 or 2 TKIs prior to 
676 progression, respectively. None of the patients who progressed were observed to have only ELN-optimal responses to 
677 first-line TKI; 3 patients had ≥1 failure, 4 had ≥1 warning and 2 had no available assessments at ELN milestones. In 
678 the 10 patients who progressed to AP and/or BP, baseline Sokal score was recorded as high for 4, intermediate for 2, 
679 low for 1 and unknown for 3.
680 b A total of 15/257 patients died during the study observation period; 5 of these patients had progressed to AP and/or 
681 BP prior to death (n=4 had blast crisis prior to death). Another 5 patients had progressed but were still alive at data 
682 collection (n=2 had blast crisis); all had received alternative treatment with 4 of 5 receiving both transplant and 
683 chemotherapy after progressing (n=1 after alternative TKI); the other patient received a transplant only.
684 AP, accelerated phase; BP, blast phase; ELN, European LeukemiaNet; TKI, tyrosine kinase inhibitor.
685































































Fig 1. Kaplan-Meier curve: time to discontinuation of first-line TKI 
Patients who had not switched from first TKI at point of data collection were censored at date of data 
collection or death. Months on first TKI were unknown for 10 patients on imatinib. TKI, tyrosine kinase 
inhibitor. 
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Fig 2. TKI treatment pathways and molecular responses for patients with ELN optimal, warning (at single vs 
multiple ELN milestones) or failure responses while on first-line TKIa To account for variations in real-world 
appointment scheduling, a window of ±1 month was applied to ELN-defined time points (3, 6 and 12 
months). In patients with multiple test results available, any patient with a failure response to first-line TKI 
at an ELN milestone (regardless of other responses achieved at earlier milestones) was classified as having a 
failure response. Patients in the optimal category had only optimal responses at an ELN milestone (3, 6 or 
12 months) with either molecular or cytogenetic assessment (where a molecular test was not available). 
Patients in the warning category had a warning at any milestone with either assessment but had no failure 
at any milestone with either assessment. Patients without assessments at any ELN milestone could not be 
categorized. Thirty-four patients had no evaluable test at any ELN milestone by either molecular or 
cytogenetic test.b Response may have been observed at any time. Duration of follow up varied; patient may 
have had ≥1 subsequent TKI switch. Forty-eight patients had ≥1 failure; 11 (23%) remained on first-line 
TKI (median follow-up, 13.8 months [IQR, 12.8-25.9 months]), and 37 (77%) switched TKIs (median 
follow-up, 25.1 months [IQR, 14.3-32.6 months]). Of those who switched, 22 had their first failure at 6 
months (BCR-ABL1IS range, 10.1%-60.1%; 2 patients had a failure according to FISH), and 15 had their 
first failure at 12 months (BCR-ABL1IS range, 1.2%-12.7%). Among these patients with a failure who 
switched TKIs, 17 (46%) and 10 (27%) achieved MMR and DMR at any time, respectively, vs 4 (36%) and 0 
patients who did not switch TKIs. Of 81 patients with warning but no failure, 52 (64%) remained on first-line 
TKI (median follow-up 28.4 months [IQR, 13.7-40.4 months]), and 29 (36%) switched TKIs (median follow-
up 30.9 months [IQR, 20.3-38.3 months]). Of those who switched TKIs, 19/29 had ≥1 additional RQ-PCR 
assessment between the initial warning and TKI switch. Of 34 patients without any quantifiable assessment 
at any ELN milestone, 27 (79%) switched TKIs. c Of 48 patients with ELN-defined failure responses, 39 were 
treated with imatinib as first-line therapy and 9 with a 2G-TKI; 38 patients (79%) also had an ELN-defined 
warning at a prior ELN time point (with either a molecular or cytogenetic test). 
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Fig 3. Disease progressiona      a Eight patients (7 on imatinib, 1 on a second-generation TKI) progressed to 
accelerated phase (AP) during the course of the study. The median time to progression was 16.5 months 
(range, 2.1-31.1; IQR, 7.5-26.4; time to progression was unknown for one patient on first-line imatinib). 
Three patients had a prior warning response at an ELN milestone (all 3 patients received imatinib as first 
TKI), and 3 patients had a failure response at an ELN milestone (2 patients received imatinib first line and 1 
patient received nilotinib). The other 2 patients who progressed to AP had no prior evaluable response at an 
ELN milestone (both patients received first-line imatinib). Treatments for progression to AP were TKIs in 3 
patients, chemotherapy in 4 patients and allogenic haematopoietic stem cell transplant (HSCT) in 5 patients. 
Six patients progressed to BP (all received first-line imatinib), including 4 who were previously recorded as 
progressing to AP. Median time from start of first-line TKI to progression to BP was 22.7 months (range 1.2- 
32.1; IQR, 17.2-30.1). Treatments for progression to BP were TKIs in 4 patients, chemotherapy in 4 
patients, allogenic HSCT in 2 patients and haploidentical allogenic HSCT in one patient. Among 4 patients 
who progressed to AP only, 2 received 1 TKI prior to progression, 1 received 3 TKIs prior to progression, and 
1 had an unknown date of disease progression. Among 4 patients who progressed to AP and BP, 2 each 
received 1 or 2 TKIs prior to their earliest progression, respectively. Among 2 patients who progressed to BP 
only, 1 each received 1 or 2 TKIs prior to progression, respectively. None of the patients who progressed 
were observed to have only ELN-optimal responses to first-line TKI; 3 patients had ≥1 failure, 4 had ≥1 
warning and 2 had no available assessments at ELN milestones. In the 10 patients who progressed to AP 
and/or BP, baseline Sokal score was recorded as high for 4, intermediate for 2, low for 1 and unknown for 
3.%"b A total of 15/257 patients died during the study observation period; 5 of these patients had 
progressed to AP and/or BP prior to death (n=4 had blast crisis prior to death). Another 5 patients had 
progressed but were still alive at data collection (n=2 had blast crisis); all had received alternative 
treatment with 4 of 5 receiving both transplant and chemotherapy after progressing (n=1 after alternative 
TKI); the other patient received a transplant only.%"AP, accelerated phase; BP, blast phase; ELN, European 
LeukemiaNet; TKI, tyrosine kinase inhibitor.%" 
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45 Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, 
46 prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it 
47 remains unclear whether real-world CML management is consistent with these goals. We report 
48 results of UK TARGET CML, a retrospective observational study of 257 patients with chronic-
49 phase CML prescribed a first-line TKI between 2013 and 2017, most of whom received first-line 
50 imatinib (n=203). Although 44% of patients required ≥1 change of TKI, these real-world data 
51 revealed that molecular assessments were frequently missed, 23% of patients with ELN-defined 
52 treatment failure did not switch TKI and kinase domain mutation analysis was performed in only 
53 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR-
54 ABL1IS ≤0.1%) and deep molecular response (DMR; BCR-ABL1IS ≤0.01%) were observed in 
55 50% and 29%, respectively, of patients treated with first-line imatinib and 63% and 54% 
56 receiving a second-generation TKI first line. MMR and DMR were also observed in 77% and 
57 44% of evaluable patients with ≥13 months’ follow-up receiving a second-generation TKI 
58 second line. We found little evidence that cardiovascular risk factors were considered during TKI 
59 management. These findings highlight key areas for improvement in providing optimal care to 
60 patients with CML.
61
62 Keywords: tyrosine kinase inhibitor, chronic myeloid leukaemia, real-world study, molecular 
63 response, management 
































































65 Tyrosine kinase inhibitors (TKIs) have revolutionised outcomes for patients with chronic 
66 myeloid leukaemia in chronic phase (CML-CP), with survival rates approaching those of the 
67 general population (Bower et al, 2016; Hoglund et al, 2013; Sasaki et al, 2015). Consequently, 
68 key considerations for optimal patient care have evolved considerably. While the primary aim 
69 remains achievement of molecular response that minimises the risk of disease progression 
70 (Baccarani et al, 2013), increasingly, complications of the treatment need to be considered. It is 
71 therefore essential for physicians to understand the best use of the available ABL1-targeting 
72 TKIs (Baccarani et al, 2013). This is the principal purpose of of the most recentthe 2013 
73 European LeukemiaNet (ELN) recommendations, which increased focus on molecular responses 
74 at 3, 6 and 12 months, with patients’ responses categorized as optimal, warning or failure 
75 (Baccarani et al, 2013). Patients experiencing failure are at particular risk of disease progression, 
76 and the guidelines recommend that such patients switch treatment and undergo assessment for 
77 BCR-ABL1 kinase domain mutations (Baccarani et al, 2013).
78
79 While the current ELN 2013 guidelines state that patients must achieve a major molecular 
80 response (MMR; BCR-ABL1 ≤0.1% on the International Scale [IS]) by 12 months for their 
81 response to be considered optimal (Baccarani et al, 2013), deeper levels of response, including 
82 MR4 (BCR-ABL1IS ≤0.01%) and MR4.5 (BCR-ABL1IS ≤0.0032%), are also recognized as 
83 important milestones (Cross et al, 2012; Etienne et al, 2014; Hehlmann et al, 2014). Some 
84 patients with a sustained deep molecular response (DMR; MR4 or better) may be eligible to 
85 attempt treatment-free remission (TFR) (Hochhaus et al, 2017b; Mahon, 2017; NCCN, 2020; 
86 Rea et al, 2018). Clinical trials have demonstrated that patients are more likely to achieve 































































87 optimal and deeper responses to first-line therapy at key ELN milestones when second-
88 generation (2G) TKIs are used rather than imatinib; however, achievement of responses in real-
89 world practice is less well studied, particularly in the second-line setting (Cortes et al, 2018a; 
90 Cortes et al, 2016; Hochhaus et al, 2016). Achievement of ELN-defined responses and how ELN 
91 guidelines are implemented in real-world settings are infrequently explored.
92
93 An increased risk of cardiovascular (CV) adverse events (AEs) has been described in patients 
94 receiving 2G- or third-generation–TKIs compared with imatinib, especially in patients with pre-
95 existing CV risk factors (Chai-Adisaksopha et al, 2016; Cortes et al, 2018b; Cortes et al, 2016; 
96 Hochhaus et al, 2016; Lipton et al, 2016). Given the excellent long-term outcomes in CML, 
97 comorbidities are now a major consideration (Jabbour et al, 2014; Saussele et al, 2015). 
98 However, in UK routine clinical practice, it is unclear how physicians assess and manage CV 
99 risk factors or how CV risk factors affect TKI management.
100
101 UK TARGET CML (CAMN107CGB12) is a retrospective observational study of baseline 
102 assessment of patients with CML-CP, TKI treatment pathways, response monitoring patterns and 
103 response rates in routine UK National Health Service (NHS) clinical practice; we compared 




108 This retrospective noninterventional study was conducted at 21 UK NHS secondary and tertiary 
109 care centres. Data were collected from paper and electronic records. Inclusion criteria included 































































110 CML-CP diagnosis at start of first-line TKI, age ≥18 years and ≥6 months of follow-up from 
111 date of first TKI (between January 2013 and April 2017). Patients prescribed first TKI in a 
112 clinical trial and patients in accelerated phase (AP) or blast phase (BP) before initiation of first 
113 TKI were excluded.
114
115 Objectives were to describe TKI treatment pathways in the UK, patient characteristics, practices 
116 for assessing and managing CV risk factors before TKI treatment, responses to first- and second-
117 line TKI therapy at ELN time points, recorded reasons for stopping/changing TKIs, adherence to 
118 ELN 2013 recommendations and disease progression frequency and management. AE data were 
119 not collected.
120
121 Data were analysed using descriptive statistics, with a cutoff date of June 6, 2018, using 
122 Microsoft Excel and STATA (version 13; StataCorp LLC, College Station, TX, USA). A study 
123 size of 200-250 patients in approximately 20 centres (maximum of 40 patients/centre) was 
124 expected to give a representative sample of patients in the UK and provide reliable quantitative 
125 and qualitative variables.
126
127 For comparison with ELN, where data were available, rResponses were categorised as optimal, 
128 warning or failure according to ELN 2013 recommendations (Baccarani et al, 2013).  If BCR-
129 ABL1 transcript levels were not available on the IS, unconverted BCR-ABL1/ABL1 percentages 
130 were used to reflect real-world practices at that centre (all centres used ABL1 as a reference 
131 gene). Two of 14 centres (14%) reported on the IS in 2013; increasing to 17/21 (81%) in 2017. 
132
































































134 Patient demographics and baseline characteristics
135 Two-hundred-fifty-seven patients (186 from 14 tertiary centres and 71 from 7 general hospitals) 
136 were enrolled between November 2015 and September 2017. Median follow-up by the data 
137 cutoff was 32.9 months (range, 12.6-58.6). Baseline characteristics are shown in Table I. 
138 Clinical characteristics (other than white blood cell counts) and risk scores at diagnosis were not 
139 well documented.
140
141 The first-line TKI was imatinib in the majority of patients (79%); reasons for first-line TKI 
142 choice were recorded for <50% of patients: clinician preference, “standard first-line choice” and 
143 “good results expected” were the most frequently cited reasons (Supplementary Table I). First-
144 line imatinib and 2G-TKIs were prescribed to 31/42 (74%) and 11/42 (26%) patients with high 
145 Sokal scores, respectively, and 23/34 (68%) and 11/34 (32%) with high European Treatment and 
146 Outcomes Study (EUTOS) scores. Patients receiving a first-line 2G-TKI were younger (median, 
147 46 years [95% CI, 41-53 years] than those receiving first-line imatinib (median, 55 years [95% 
148 CI, 52-59 years]; Mann-Whitney U test, P = 0.0128). 
149
150 CV risk factors and other documented comorbidities at baseline
151 Among all patients, 149 (58%) had ≥1 recorded comorbidity at baseline (Table I). Seventy-four 
152 patients (36%) receiving imatinib had CV comorbidities at baseline vs 7 (13%) receiving a 2G-
153 TKI (Table II). Only 74 patients (29%) had baseline blood pressure documented; 33 (45%) had 
154 stage ≥2 hypertension (Supplementary Table II) (Whelton et al, 2018).
155































































156 Exact levels of baseline blood glucose were documented in 58 patients (23%); documentation 
157 occurred more often in patients treated with first-line 2G-TKI (20/54 [37%]) vs imatinib (38/203 
158 [19%]). Baseline low-density lipoprotein and total cholesterol levels were recorded in 23 (9%) 
159 and 40 (16%) patients. CV risk assessment tool use was documented for 10 patients (4%), with 
160 the validated QRISK2 tool used in 3 (1%).
161
162 Response monitoring practices
163 Within 12 months of starting first-line TKI, 250 patients (97%) had ≥1 real-time quantitative 
164 polymerase chain reaction (RQ-PCR) assessment and 221 patients (86%) had ≥3 RQ-PCR 
165 assessments. Two-hundred-four (79%), 177 (69%), and 162 (63%) patients had assessments at 
166 the 3-, 6-, or 12-month ELN milestones (regardless of TKI line), respectively. Cytogenetic 
167 testing (chromosome banding analysis or fluorescence in situ hybridization) was conducted less 
168 frequently. Frequency of assessments at ELN milestones on first and second TKI are described 
169 in Table III.
170
171 First-line TKI therapy
172 Median follow-up duration on first-line TKI and molecular responses to first-line TKI therapy 
173 are shown in Table IV. Time to discontinuation of first TKI for patients on imatinib vs 2G-TKI 
174 is shown in Fig 1. For patients receiving imatinib or nilotinib, respective median starting doses 
175 were 400 or 600 mg/day; 24/203 (12%) and 8/50 (16%) had dose reductions, while 14% and 
176 12% had dose interruptions.
177































































178 Quantifiable molecular or cytogenetic assessments were performed at ≥1 ELN milestone during 
179 first-line TKI in 223 patients (87%) (Fig 2). Forty-eight patients had ≥1 failure; 11 (23%) 
180 remained on first-line TKI (median follow-up, 13.8 months [interquartile range (IQR), 12.8-
181 25.9]), and 37 (77%) switched TKIs (median follow-up, 25.1 months [IQR, 14.3-32.6]).
182
183 Second-line TKI therapy
184 At least one TKI switch occurred in 113 patients (44%); 54 (21%) switched more than once. 
185 Reasons for the first switch were resistance in 73 (65%), intolerance in 38 (34%) and other 
186 reasons in 2 (2%) (Supplementary Table III). BCR-ABL1 kinase domain mutational analysis 
187 was performed prior to the first switch in 24 patients (21%), including 20 (27%) who switched 
188 due to resistance and 4 (10%) who switched due to intolerance or other reasons. Thirteen patients 
189 (12%) switched to imatinib, 68 (60%) to nilotinib, 20 (18%) to dasatinib, 11 (10%) to bosutinib 
190 and one (1%) to ponatinib (Supplementary Table IV). For patients receiving second-line 
191 imatinib, nilotinib, dasatinib and bosutinib, median starting doses (range) were 400 (200-400), 
192 600 (200-800), 100 (50-100) and 300 (100-500) mg/day, respectively.
193
194 Median follow-up duration after switching to second TKI was 23.7 months (range, 1.2-54.1) 
195 (Table V). MMR at any time and DMR at any time were observed in 37/51 (73%) and 21/51 
196 (41%) patients with ≥13 months’ follow-up on second line. Molecular responses to second-line 
197 TKI for all patients regardless of follow-up duration are shown in Supplementary Table V.
198































































199 Of 113 patients who switched TKI at least once, 18 (16%) had failure on second-line TKI 
200 (Supplementary Fig 1); 7 (39%) remained on that TKI (median follow-up, 24.3 months [IQR, 
201 11.6-31.0]), while 11 (61%) switched again (median follow-up, 27.5 months [IQR, 16.4-33.8]).
202
203 Kinase domain mutation analysis
204 BCR-ABL1 kinase domain mutational analysis was performed prior to the first switch in 24 
205 patients (21%), including 20 (27%) who switched due to resistance and 4 (10%) who switched 
206 due to intolerance or other reasons. Clinically actionable mutations were identified in 6 patients 
207 (Supplementary Table VI).
208
209 Overall TKI pathways
210 Among all patients, 144 (56%) received only a first-line TKI, and 59 (23%), 35 (14%), 16 (6%) 
211 and 3 (1%) received 2, 3, 4 and 5 TKIs, respectively; sequences of TKI received are described in 
212 Supplementary Table IV. Eleven patients received the same TKI in multiple lines of therapy.
213
214 Disease progression
215 Ten patients progressed to AP and/or BP, and 15 patients died (10 in CP and 5 after progression). 
216 Survival outcomes and treatments to manage progression are summarized in Fig 3.
217
218 Discussion
219 The management of CML has undergone dramatic changes; however, it remains unclear whether 
220 real-world practice in the UK has evolved with these developments. We conducted the UK 
221 TARGET CML study to assess this question, with a particular focus on (1) TKI treatment 































































222 pathways, (2) implementation of ELN recommendations for molecular-based patient 
223 management, (3) attainment of DMR with first- and second-line TKI in real-world practice and 
224 (4) assessment of baseline CV risk factors.
225
226 Despite relatively short median follow-up (<33 months), almost half of patients switched from 
227 first-line TKI, most often due to resistance (65%). In addition, 21% of patients received ≥3 lines 
228 of TKIs. This frequency of TKI switching was somewhat higher than that observed in 
229 prospective clinical trials, such as the pivotal trial of frontline imatinib (International 
230 Randomized Study of Interferon and STI571 [IRIS]), which reported that 34% of patients 
231 discontinued treatment after 6 years of follow-up, although no other alternative TKI was 
232 available at the time of IRIS recruitment (Hochhaus et al, 2009). In IRIS long-term follow-up 
233 (median, 10.9 years), imatinib discontinuation was most frequently attributed to unsatisfactory 
234 therapeutic effect (15.9%), withdrawal of consent (10.3%), or AEs (6.9%) (Hochhaus et al, 
235 2017a). Similarly, in the frontline trial of nilotinib (Evaluating Nilotinib Efficacy and Safety in 
236 Clinical Trials–Newly Diagnosed Patients [ENESTnd]), treatment discontinuations were most 
237 frequently due to suboptimal response/treatment failure or AEs/abnormal laboratory values (12% 
238 each by the 5-year data cutoff among patients allocated to nilotinib 300 mg twice daily) 
239 (Hochhaus et al, 2016). We found that in real-world practice, approximately half of patients 
240 required a change of TKI, highlighting the importance of optimal monitoring of molecular 
241 responses and treatment-related side effects to ensure proper use of TKIs and timely switching. 
242 These data also demonstrated the ongoing challenge of establishing a satisfactory, long-term 
243 treatment, with multiple TKI switches being common.
244































































245 Although 58% of patients had a recorded comorbidity, patients generally had poorly documented 
246 baseline clinical characteristics and prognostic scores. Demographic and baseline characteristics 
247 were not dissimilar from those of other real-world cohorts (Goldberg et al, 2017; Hoglund et al, 
248 2013; Nesr et al, 2018), although prognostic scores were better documented (98%) in the 
249 Swedish CML registry (Hoglund et al, 2013). CV events have been reported to be increased with 
250 2G-TKIs (Chai-Adisaksopha et al, 2016; Cortes et al, 2016; Hochhaus et al, 2016), and CV risk 
251 factors should therefore be carefully considered when choosing a TKI. Even with first-line 
252 imatinib, it is important to assess CV risk given that approximately half of patients will require a 
253 switch to a 2G-TKI at some point. Although late complications with 2G-TKIs were not fully 
254 understood or evaluable at the time of ELN 2013, the guidelines nevertheless recommended 
255 continued clinical monitoring of all patients. Several CV risk factors were very poorly 
256 documented in our cohort, and any use of validated CV risk tools, such as QRISK2, was rarely 
257 documented. Baseline blood pressure was documented in fewer than one-third of patients; when 
258 baseline blood pressure was recorded, it was often elevated, with 3 patients in hypertensive 
259 crisis, illustrating the importance of documenting this parameter so that hypertension can be 
260 managed appropriately. However, some evidence was observed that CV comorbidities at 
261 baseline played a role in first-line TKI choice, with patients appearing more likely to receive 
262 first-line imatinib if a CV comorbidity was documented.
263
264 Currently, the UK National Institute for Health and Care Excellence (NICE) recommends NHS 
265 funding in England of imatinib, nilotinib or dasatinib in the first line and nilotinib, dasatinib, 
266 bosutinib or ponatinib in later lines (NICE, 2018). In this cohort, first-line treatment was mostly 
267 imatinib or nilotinib (<2% received first-line dasatinib), and second-line treatment was mostly 































































268 nilotinib, reflecting NICE recommendations at the start of treatment for these patients (dasatinib 
269 was not routinely available). Patients were more likely to receive first-line 2G-TKIs than 
270 imatinib if they were younger and had no documented comorbidities. Overall, prognostic scores 
271 were poorly documented despite strong evidence that these risk scores remain highly predictive 
272 of disease response in the TKI era (Hochhaus et al, 2016). We did not find evidence that 
273 prognostic scores played a major role in first-line TKI choice, with a majority of patients 
274 identified as high risk by Sokal, EUTOS or Hasford criteria being treated with imatinib. Overall, 
275 4% of patients progressed to AP and/or BP, corresponding well with the results of the Swedish 
276 CML registry (3% by 12 months) (Hoglund et al, 2013).
277
278 One key finding of this study is that ELN 2013 monitoring recommendations were not 
279 consistently implemented. Patients frequently did not have assessments at recommended time 
280 points. This finding is consistent with those from the SIMPLICITY study, which reported that 
281 monitoring was conducted less frequently than recommended, although with higher frequency in 
282 Europe than the United States (Goldberg et al, 2017). This finding is important because a 
283 previous study showed that patients without frequent molecular monitoring were at higher risk of 
284 disease progression (Goldberg et al, 2013). In addition, frequent molecular monitoring (3-4 times 
285 per year) was associated with greater TKI treatment adherence in patients with CML (Guerin et 
286 al, 2014).
287
288 Overall, in our study, 86% of patients had ≥3 molecular response tests during their first year of 
289 TKI treatment, while SIMPLICITY reported 46% for Europe (Goldberg et al, 2017), a finding 
290 that potentially reflects UK-specific practice or changes in practice over time (UK patients who 































































291 were first treated in 2013-2017 were compared with SIMPLICITY patients first treated in 2010-
292 2015). Furthermore, our UK study observed a relatively high level of testing for early molecular 
293 response (EMR) at 3 months (81%) compared with SIMPLICITY (32%), indicating rapid 
294 adoption of molecular monitoring at early milestones in the UK (Goldberg et al, 2017).
295
296 However, despite a generous 1-month window applied around ELN milestones, a large 
297 proportion of patients (≈20%-30%) were still without evaluable molecular or cytogenetic test 
298 results at any given time point during their first year of TKI treatment. Moreover, 13% of 
299 patients had no evaluable molecular or cytogenetic result at any ELN milestone during the first 
300 year of TKI treatment.
301
302 ELN recommended that a patient with ELN-defined failure should have their TKI switched to 
303 reduce the risk of progression. Nevertheless, a number of patients in TARGET remained on first-
304 line TKI despite ELN-defined treatment failure.
305
306 Strikingly, BCR-ABL1 kinase domain mutational analyses, recommended by ELN in warning or 
307 failure, were infrequently performed, even in patients with documented resistance, despite the 
308 known importance of mutation status for subsequent TKI selection. Patients did not always have 
309 recommended baseline assessments such as qualitative PCR despite its importance in 
310 determining BCR-ABL1 transcript type, which can affect future molecular monitoring, especially 
311 at the low levels before consideration for TFR. Furthermore, although bone marrow and 
312 cytogenetic analysis still have an essential role in assessment of patients at baseline, many 
313 patients were managed without bone marrow or cytogenetic analysis. Bone marrow evaluation 































































314 before TKI switching was infrequently performed, which may reflect the current use of PCR 
315 thresholds for interpretation of resistance.
316
317 Clinical trials have shown that 2G-TKIs lead to improved rates of molecular responses compared 
318 with imatinib (Cortes et al, 2018a; Cortes et al, 2016; Hochhaus et al, 2016). In this cohort, 
319 observed rates of EMR and MMR at ELN milestones and DMR at any time during first-line TKI 
320 were higher with 2G-TKIs than with imatinib, confirming the results in this real-world setting. 
321 While EMR and MMR were defined as optimal responses in ELN 2013 (Baccarani et al, 2013), 
322 treatment goals are evolving to include deeper responses and TFR (Hochhaus et al, 2017b; 
323 NCCN, 2020; Rea et al, 2018). Studies have shown that deeper molecular responses were 
324 associated with improved outcomes compared with complete cytogenetic response (Etienne et al, 
325 2014; Hehlmann et al, 2014), and a sustained DMR is a prerequisite for attempting TFR in both 
326 clinical practice guidelines (Hochhaus et al, 2017b; NCCN, 2020; Rea et al, 2018) and clinical 
327 trials (Mahon et al, 2018; Ross et al, 2018). Clinical studies have demonstrated that 2G-TKIs can 
328 also lead to improved rates of DMR in the second line (Hughes et al, 2017). Results from our 
329 study showed that patients switching from first-line treatment may achieve not only optimal 
330 responses but also deeper responses, including patients with prior resistance or ELN-defined 
331 failure.
332
333 A criticism of observational studies is the increased risk of selection bias and confounding, 
334 precluding the robust analysis and conclusions provided by randomized controlled trials. 
335 However, real-world evidence plays an important role in allowing physicians to reflect on 
336 current practice. Our study demonstrated that almost half of patients required TKI switch in real-































































337 world practice and that optimal and deep responses can be achieved by patients who switch. 
338 However, inadequate CV risk assessment, response monitoring, and mutational analysis 
339 increased the risk of inappropriate patient management and, as such, the findings of this study 
340 highlighted key areas for improvement in care for patients with CML. Further consideration for 
341 improving implementation of guidelines in real-world clinical practice, including very recent 
342 updates to the ELN recommendations (Hochhaus et al 2020),  is warranted.
343
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Male 144 (56) 119 (59) 25 (46) 24 (48)
Female 113 (44) 84 (41) 29 (54) 26 (52)














Time from CML diagnosis to start of first TKI, 
median (IQR), days
7.0 (1.0-20.0) 8.0 (2.0-20.3) 6.0 (1.0-11.0) 6.0 (1.0-11.0)
Assessments prior to first-line TKI, n (%)
RQ-PCR 169 (66) 140 (69) 29 (54) 26 (52)
Qualitative PCR (b2a2, b3a2, other) 140 (54) 107 (53) 33 (61) 30 (60)
CBA 180 (70) 146 (72) 34 (63) 31 (62)
FISH 155 (60) 117 (58) 38 (70) 34 (68)
CBA or FISH (bone marrow) 154 (60) 119 (59) 35 (65) 32 (64)
CBA or FISH (peripheral blood) 54 (21) 45 (22) 9 (17) 9 (18)
Both CBA/FISH and RQ-PCR 139 (54) 117 (58) 22 (41) 20 (40)
Treatment for CML prior to first-line TKI, n (%)
Yes 126 (49) 97 (48) 29 (54) 26 (52)
Prior treatmenta,b
Hydroxycarbamide 116 (92) 89 (92) 27 (93) 24 (92)
Leukapheresis 2 (2) 2 (2) 0 0
Anagrelide 1 (1) 1 (1) 0 0
Interferon 1 (1) 1 (1) 0 0
Aspirin 1 (1) 0 1 (3) 1 (4)
No 128 (50) 104 (51) 24 (44) 23 (46)
Unknown 3 (1) 2 (1) 1 (2) 1 (2)
Ph chromosome at baseline
Yes 212 (82) 175 (86) 37 (69) 35 (70)
No 3 (1) 1 (<1) 2 (4) 2 (4)
Unknown 42 (16) 27 (13) 15 (28) 13 (26)
Clinical characteristics








Unknown, n (%)c 4 (2) 1 (<1) 3 (6) 2 (4)








Unknown, n (%)c 14 (5) 11 (5) 3 (6) 2 (4)
Basophils, median (IQR), % 3.9 (2.0-7.0) 3.3 (2.0-6.0) 5.0 (2.3-8.0) 4.0 (2.3-8.3)
Unknown, n (%)c  59 (23) 46 (23) 13 (24) 13 (26)
Eosinophils, median (IQR), % 2.0 (1.1-3.7) 2.0 (1.1-3.5) 2.0 (1.3-3.7) 2.0 (1.3-3.0)
Unknown, n (%)c 58 (23) 45 (22) 13 (24) 13 (26)
Blasts, median (IQR) (%) 2.0 (1.0-4.8) 2.0 (1.0-3.4) 3.0 (1.6-8.4) 3.0 (1.5-6.0)
Unknown, n (%)c 101 (39) 77 (38) 24 (44) 23 (46)
Spleen size below costal margin, median (IQR), 
cmd
1.3 (0.0-10.1) 1.0 (0.0-10.1) 4.0 (0.0-10.3) 2.0 (0.0-10.0)
Unknown, n (%)c 85 (33) 67 (33) 18 (33) 17 (34)
Sokal risk score, n (%)e
Low risk 52 (20) 43 (21) 9 (17) 8 (16)
Intermediate risk 54 (21) 41 (20) 13 (24) 13 (26)
High risk 42 (16) 31 (15) 11 (20) 9 (18)































































No score recorded and required components not 
all recorded
109 (42) 88 (43) 21 (39) 20 (40)
EUTOS score, n (%)f
Low risk 110 (43) 90 (44) 20 (37) 19 (38)
High risk 34 (13) 23 (11) 11 (20) 9 (18)
No score recorded and required components not 
all recordedg
113 (44) 90 (44) 23 (43) 22 (44)
Hasford score, n (%)h
Low risk 25 (10) 19 (9) 6 (11) 5 (10)
Intermediate risk 35 (14) 32 (16) 3 (6) 3 (6)
High risk 19 (7) 13 (6) 6 (11) 4 (8)
No score recorded and required components not 
all recorded
178 (69) 139 (68) 39 (72) 38 (76)
Comorbidities, n (%)
None recorded 108 (42) 80 (39) 28 (52) 26 (52)
≥1 recordedi,j 149 (58) 123 (61) 26 (48) 24 (48)
CV comorbidities 81 (32) 74 (36) 7 (13) 6 (12)
Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Respiratory disease 20 (8) 17 (8) 3 (6) 3 (6)
Renal disease 16 (6) 14 (7) 2 (4) 2 (4)
Non-haematological cancer 9 (4) 8 (4) 1 (2) 1 (2)
Hepatic disease 4 (2) 3 (1) 1 (2) 1 (2)
Other 86 (33) 70 (34) 16 (30) 15 (30)
552 2G-TKI, second-generation tyrosine kinase inhibitor; CBA, chromosome banding analysis; CML, chronic myeloid 
553 leukaemia; CV, cardiovascular; EUTOS, European Treatment and Outcomes Study; FISH, fluorescence in situ 
554 hybridization; IQR, interquartile range; Ph, Philadelphia chromosome; RQ-PCR, real-time quantitative polymerase 
555 chain reaction; WBC, white blood cell.
556 a Patients may have received multiple prior treatments.
557 b Proportion of patients with each prior treatment was calculated out of the total number of patients who received 
558 prior treatment.
559 c Proportion of patients with unknown clinical characteristics was calculated out of the total number of patients in 
560 each column.
561 d Spleens reported to be “normal” or “nonpalpable” were considered to be 0 cm below the costal margin.
562 e Among 148 patients who received any first-line TKI and had an available Sokal risk score at diagnosis, the score 
563 was documented for 96 (65%) and not documented and instead calculated during this analysis for 52 (35%).
564 f Among 144 patients who received any first-line TKI and had an available EUTOS risk score at diagnosis, the score 
565 was documented for 36 (25%) and not documented and instead calculated during this analysis for 108 (75%).
566 g Includes patients who had a risk category recorded but no score recorded.
567 h Hasford scores were not collected in case report forms and were calculated if required data were available.
568 i Patients may have had multiple comorbidities.
569 j Proportion of patients with each comorbidity was calculated out of the total number of patients in each column.
570
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Diabetes 25 (10) 21 (10) 4 (7) 4 (8)
Smoking
Documenteda 174 (68) 140 (69) 34 (63) 32 (64)
Current smoker 38 (22) 35 (25) 3 (9) 3 (9)
Ex-smoker 46 (26) 39 (28) 7 (21) 6 (19)
Never smoked 88 (51) 65 (46) 23 (68) 22 (69)
Unclear 2 (1)b 1 (1)b 1 (3)b 1 (3)b
BMI >30 documented 16 (6) 14 (7) 2 (4) 2 (4)
CV comorbidities
None recorded 176 (68) 129 (64) 47 (87) 44 (88)
≥1 recordedc,d 81 (32) 74 (36) 7 (13) 6 (12)
Hypertension 58 (23) 52 (26) 6 (11) 5 (10)
Hyperlipidaemia 28 (11) 26 (13) 2 (4) 2 (4)
Coronary artery disease 14 (5) 12 (6) 2 (4) 2 (4)
Myocardial infarction 11 (4) 10 (5) 1 (2) 1 (2)
Coronary artery bypass graft 9 (4) 8 (4) 1 (2) 1 (2)
Arrhythmias 8 (3) 7 (3) 1 (2) 1 (2)
Cerebrovascular accident 4 (2) 4 (2) 0 0
Transient ischemic attack 4 (2) 3 (1) 1 (2) 1 (2)
Congestive heart failure 3 (1) 2 (1) 1 (2) 1 (2)
Unstable angina 2 (1) 2 (1) 0 0
Percutaneous coronary 
intervention
2 (1) 2 (1) 0 0
Peripheral vascular disease 2 (1) 2 (1) 0 0
History of CV disease
Not documented 101 (39) 80 (39) 21 (39) 20 (40)
Documentation unknowne 1 (<1) 1 (<1) 0 0
Documentedf 155 (60) 122 (60) 33 (61) 30 (60)
No history 26 (17) 23 (19) 3 (9) 3 (10)
Details of history not 
provided
104 (67) 76 (62) 28 (85) 25 (83)
Details of history provided 25 (16) 23 (19) 2 (6) 2 (7)
Family history of CV disease
Not documented 159 (62) 128 (63) 31 (57) 29 (58)
Documentation unknowne 1 (<1) 1 (<1) 0 0
Documented 97 (38) 74 (36) 23 (43) 21 (42)
573 2G-TKI, second-generation tyrosine kinase inhibitor; BMI, body mass index; CV, cardiovascular.
574 a Proportion of patients in each smoking category was calculated based on the number of patients with documented 
575 smoking status.
576 b Two patients were recorded as “does not smoke”; it was unclear whether they were ex-smokers or never smoked.
577 c Patients could be listed as having >1 CV comorbidity.
578 d Proportion of patients with CV comorbidities was calculated based on total number of patients in each column.
579 e One patient was transferred from another hospital prior to TKI treatment; it was unclear if this patient’s personal or 
580 family history of vascular disease had been documented prior to TKI treatment.
581 f Proportion of patients within each category was calculated based on the number of patients who had documented 
582 CV disease history.
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584 Table III. Frequency of molecular and cytogenetic assessments at ELN milestones for patients on 















3 monthsa 180/223 (81) 143/173 (83) 37/50 (74) 35/47 (74)
6 monthsb 141/199 (71) 105/154 (68) 36/45 (80) 34/42 (81)
12 monthsc 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
CBA/FISH
3 monthsa 15/223 (7) 15/173 (9) 0/50 (0) 0/47 (0)
6 monthsb 9/199 (5) 8/154 (5) 1/45 (2) 1/42 (2)
12 monthsc 2/170 (1) 2/132 (2) 0/38 (0) 0/35 (0)
CBA/FISH and/or RQ-PCR
3 monthsa 186/223 (83) 148/173 (86) 38/50 (76) 36/47 (77)
6 monthsb 151/199 (76) 114/154 (74) 37/45 (82) 35/42 (83)
12 monthsc 117/170 (69) 95/132 (72) 22/38 (58) 21/35 (60)
Second TKI
RQ-PCR
3 monthsa 63/82 (77) 8/10 (80) 55/72 (76) 43/54 (80)
6 monthsb 44/66 (67) 4/8 (50) 40/58 (69) 31/46 (67)
12 monthsc 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
CBA or FISH
3 monthsa 12/82 (15) 2/10 (20) 10/72 (14) 9/54 (17)
6 monthsb 4/66 (6) 0/8 (0) 4/58 (7) 4/46 (9)
12 monthsc 1/52 (2) 0/8 (0) 1/44 (2) 1/39 (3)
CBA/FISH and/or RQ-PCR
3 monthsa 65/82 (79) 8/10 (80) 57/72 (79) 45/54 (83)
6 monthsb 45/66 (68) 4/8 (50) 41/58 (71) 32/46 (70)
12 monthsc 27/52 (52) 4/8 (50) 23/44 (52) 19/39 (49)
≥1 assessment at an ELN milestone (first- or 
second-line TKI)a
239/257 (93) 189/203 (93) 50/54 (93) 48/50 (96)
586 CBA, chromosome banding analysis; ELN, European LeukemiaNet; FISH, fluorescence in situ hybridization; RQ-
587 PCR, real-time quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.
588 a Denominator included patients with ≥4 months’ follow-up on that TKI.
589 b Denominator included patients with ≥7 months’ follow-up on that TKI.
590 c Denominator included patients with ≥13 months’ follow-up on that TKI.
591































































592 Table IV. Summary of molecular responses to first-line TKI therapya









































EMR at 3 months 
















MMR by 12 
months (±1 
month), n (%)
84 (41) 28 (52) 112 (44) 71 (35) 26 (48) 25 (50) 97 (38)
MMR at any 
time, n (%)
156 
(77) 42 (78) 198 (77) 102 (50) 34 (63) 32 (64) 136 (53)
DMR at any 
time, n (%) 95 (47) 35 (65) 130 (51) 58 (29) 29 (54) 27 (54) 87 (34)
593 2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular 
594 response; IS, International Scale; MMR, major molecular response.
595 a Patients could appear in multiple molecular response categories. Molecular responses were assessed as EMR 
596 (BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any time and DMR (BCR-
597 ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, a window of ±1 month 
598 was applied to ELN-defined time points; if multiple assessments were available within the window, the one closest 
599 to the time point was used.
600 b Fifty patients received first-line nilotinib, and 4 received first-line dasatinib.
601 c The columns for overall response reported the duration of follow-up for all TKI therapies, including later-line TKIs 
602 in patients who switched from their first-line TKI (from start of first-line TKI to most recent data collection, akin to 
603 an intention-to-treat analysis). The columns for first-line TKI therapy reported the duration of follow-up for only 
604 first-line TKI therapy (from start of first-line TKI to most recent data collection or death in patients who continued 



































































609 Table V. Summary of molecular responses after switching to second-line TKI therapya






















































EMR at 3 months 
(±1 month) in 
patients with 
BCR-ABL1 at 3 
months, n (%)
75/85 (88) 11/11 (100) 64/74 (86) 48/53 (91) 47/55 (85) 28/30 (93)
EMR at 3 months 
(±1 month) on 






59/70 (84) 10/10 (100) 49/60 (82) 38/45 (84) 39/47 (83) 20/23 (87)
MMR by 12 
months (±1 
month) on second 
TKI, n (%)g
30/50 (60) 4/7 (57) 26/43 (60) 24/38 (63) 21/35 (60) 9/15 (60)
MMR at any time 
on second TKI, n 
(%)g
37/51 (73) 4/8 (50) 33/43 (77) 29/38 (76) 27/36 (75) 10/15 (67)
DMR at any time 
on second TKI, n 
(%)g
21/51 (41) 2/8 (25) 19/43 (44) 17/38 (45) 15/36 (42) 6/15 (40)
610 2G-TKI, second-generation tyrosine kinase inhibitor; DMR, deep molecular response; EMR, early molecular 
611 response; IS, International Scale; MMR, major molecular response.
612 a Patients could appear in multiple molecular response categories. Molecular responses after switch to second TKI 
613 were assessed as EMR (BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any 
614 time and DMR (BCR-ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, 
615 a window of ±1 month was applied to ELN-defined time points; if multiple assessments were available within the 
616 window, the one closest to the time point was used.
617 b Switched to 2G-TKI (n=68 nilotinib, n=20 dasatinib, n=11 bosutinib, n=1 ponatinib).
618 c Switched for intolerance (n=38) or switched for another reason (n=2).
619 d Duration from start of second-line TKI to last data collection or death (included patients with ≥1 switch).
620 e Duration from start of second-line TKI to last data collection, date of switch to a third-line TKI, or death.
621 f EMR defined as BCR-ABL1IS ≤10% at 3 months (±1 month); only those patients with BCR-ABL1 available at 3 
622 months were included.
623 g MMR (≤0.1% BCR-ABL1); DMR (≤0.01% BCR-ABL1); only those patients with ≥13 months’ follow-up were 
624 included.































































625 Fig 1. Kaplan-Meier curve: time to discontinuation of first-line TKI
626
627
628 Patients who had not switched from first TKI at point of data collection were censored at date of 
629 data collection or death. Months on first TKI were unknown for 10 patients on imatinib. TKI, 
630 tyrosine kinase inhibitor.
631































































633 Fig 2. TKI treatment pathways and molecular responses for patients with ELN optimal, 




638 a To account for variations in real-world appointment scheduling, a window of ±1 month was applied to ELN-
639 defined time points (3, 6 and 12 months). In patients with multiple test results available,; any patient with a failure 
640 response to first-line TKI at an ELN milestone (regardless of other responses achieved at earlier milestones) was 































































641 classified as having a failure responsefailure. Patients in the optimal category had only optimal responses at an ELN 
642 milestone (3, 6 or 12 months) with either molecular or cytogenetic assessment (where a molecular test was not 
643 available). Patients in the warning category had a warning at any milestone with either assessment but had no failure 
644 at any milestone with either assessment. Patients without assessments at any ELN milestone could not be 
645 categorized. Thirty-four patients had no evaluable test at any ELN milestone by either molecular or cytogenetic test.
646 b Response may have been observed at any time. Duration of follow up varied; patient may have had ≥1 subsequent 
647 TKI switch. Forty-eight patients had ≥1 failure; 11 (23%) remained on first-line TKI (median follow-up, 13.8 
648 months [IQR, 12.8-25.9 months]), and 37 (77%) switched TKIs (median follow-up, 25.1 months [IQR, 14.3-32.6 
649 months]). Of those who switched, 22 had their first failure at 6 months (BCR-ABL1IS range, 10.1%-60.1%; 2 patients 
650 had a failure according to FISH), and 15 had their first failure at 12 months (BCR-ABL1IS range, 1.2%-12.7%). 
651 Among these patients with a failure who switched TKIs, 17 (46%) and 10 (27%) achieved MMR and DMR at any 
652 time, respectively, vs 4 (36%) and 0 patients who did not switch TKIs. Of 81 patients with warning but no failure, 
653 52 (64%) remained on first-line TKI (median follow-up 28.4 months [IQR, 13.7-40.4 months]), and 29 (36%) 
654 switched TKIs (median follow-up 30.9 months [IQR, 20.3-38.3 months]). Of those who switched TKIs, 19/29 had 
655 ≥1 additional RQ-PCR assessment between the initial warning and TKI switch. Of 34 patients without any 
656 quantifiable assessment at any ELN milestone, 27 (79%) switched TKIs. 
657 c Of 48 patients with ELN-defined failure responses, 39 were treated with imatinib as first-line therapy and 9 with a 
658 2G-TKI; 38 patients (79%) also had an ELN-defined warning at a prior ELN time point (with either a molecular or 
659 cytogenetic test).
660 DMR, deep molecular response; ELN, European LeukemiaNet; EMR, early molecular response; FISH, fluorescence 
661 in situ hybridization; IQR, interquartile range; IS, International Scale; MMR, major molecular response; RQ-PCR, 
662 real-time quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.































































663 Fig 3. Disease progressiona
664
665
666 a Eight patients (7 on imatinib, 1 on a second-generation TKI) progressed to accelerated phase (AP) during the course 
667 of the study. The median time to progression was 16.5 months (range, 2.1-31.1; IQR, 7.5-26.4; time to progression 
668 was unknown for one patient on first-line imatinib). Three patients had a prior warning response at an ELN milestone 
669 (all 3 patients received imatinib as first TKI), and 3 patients had a failure response at an ELN milestone (2 patients 
670 received imatinib first line and 1 patient received nilotinib). The other 2 patients who progressed to AP had no prior 
671 evaluable response at an ELN milestone (both patients received first-line imatinib). Treatments for progression to 
672 AP were TKIs in 3 patients, chemotherapy in 4 patients and allogenic haematopoietic stem cell transplant (HSCT) in 
673 5 patients. Six patients progressed to BP (all received first-line imatinib), including 4 who were previously recorded 
674 as progressing to AP. Median time from start of first-line TKI to progression to BP was 22.7 months (range 1.2- 32.1; 
675 IQR, 17.2-30.1). Treatments for progression to BP were TKIs in 4 patients, chemotherapy in 4 patients, allogenic HSCT 
676 in 2 patients and haploidentical allogenic HSCT in one patient. Among 4 patients who progressed to AP only, 2 
677 received 1 TKI prior to progression, 1 received 3 TKIs prior to progression, and 1 had an unknown date of disease 
678 progression. Among 4 patients who progressed to AP and BP, 2 each received 1 or 2 TKIs prior to their earliest 
679 progression, respectively. Among 2 patients who progressed to BP only, 1 each received 1 or 2 TKIs prior to 
680 progression, respectively. None of the patients who progressed were observed to have only ELN-optimal responses to 
681 first-line TKI; 3 patients had ≥1 failure, 4 had ≥1 warning and 2 had no available assessments at ELN milestones. In 
682 the 10 patients who progressed to AP and/or BP, baseline Sokal score was recorded as high for 4, intermediate for 2, 
683 low for 1 and unknown for 3.
684 b A total of 15/257 patients died during the study observation period; 5 of these patients had progressed to AP and/or 
685 BP prior to death (n=4 had blast crisis prior to death). Another 5 patients had progressed but were still alive at data 































































686 collection (n=2 had blast crisis); all had received alternative treatment with 4 of 5 receiving both transplant and 
687 chemotherapy after progressing (n=1 after alternative TKI); the other patient received a transplant only.
688 AP, accelerated phase; BP, blast phase; ELN, European LeukemiaNet; TKI, tyrosine kinase inhibitor.
689
































































Supplementary Table I. Reasons for choice of first-line TKI recorded for ≥2% of all 
patients








Known reasonsb 113 (44%) 92 (45) 21 (39)
Clinician preference 26 (10) 18 (9) 8 (15)
Standard first-line choice 20 (8) 17 (8) 3 (6)
Good results expected 17 (7) 15 (7) 2 (4)
Ease of administration 9 (4) 9 (4) 0
Ineligibility for clinical trial/no trial 
available
9 (4) 9 (4) 0
Cardiovascular comorbidities 9 (4) 9 (4) 0
Low risk 7 (3) 7 (3) 0
Tolerability/side effect profile 7 (3) 6 (3) 1 (2)
Perceived as better option 
compared with others
7 (3) 6 (3) 1 (2)
Patient choice 7 (3) 5 (2) 2 (4)
Local or network guidance 7 (3) 7 (3) 0
Smoker 6 (2) 6 (3) 0
Patient age 3 (1) 3 (1) 0
Diabetes 3 (1) 3 (1) 0
High Sokal risk score 3 (1) 1 (<1) 2 (4)
Renal comorbidities 2 (1) 2 (1) 0
Started treatment in another 
country (and moved to United 
Kingdom)
2 (1) 0 2 (4)
Intermediate Sokal risk 1 (<1) 0 1 (2)
Low QRISK 1 (<1) 0 1 (2)
Reasons unknown 144 (56) 111 (55) 33 (61)
2G-TKI, second-generation tyrosine kinase inhibitor.
a Percentages were calculated out of total number of patients in each column.
b Some patients had multiple reasons recorded.










































































Documenteda 74 (29) 62 (31) 12 (22) 11 (22)
Normal
(SBP <120 mm Hg and 
DBP <80 mm Hg)
14 (19) 11 (18) 3 (25) 3 (27)
Elevated
(SBP 120-129 mm Hg and 
DBP <80 mm Hg)
15 (20) 13 (21) 2 (17) 1 (9)
Stage 1 hypertension
(SBP 130-139 mm Hg or 
DBP 80-89 mm Hg)
12 (16) 8 (13) 4 (33) 4 (36)
Stage 2 hypertension
(SBP ≥140 mm Hg or DBP 
≥90 mm Hg)
30 (41) 27 (44) 3 (25) 3 (27)
Hypertensive crisis
(SBP >180 mm Hg and/or 
DBP >120 mm Hg)
3 (4) 3 (5) 0 0
Not documented 182 (71) 140 (69) 42 (78) 39 (78)
Not known whether 
documented 1 (<1)
b 1 (<1)b 0 0
2G-TKI, second-generation tyrosine kinase inhibitor; DBP, diastolic blood pressure; SBP, systolic blood pressure.
a Proportion of patients in each blood pressure category is calculated out of the number of patients with documented 
blood pressure.
b One patient was transferred from another hospital prior to TKI treatment; it was unclear if this patient’s blood 
pressure had been documented prior to TKI treatment.































































Supplementary Table III. Reasons for switch from first-line TKI
n (%)a
Patients who switched from first-line TKI
(n=113)b
Resistancec 73 (65)
Intolerance or other reasons 40 (35)
Intolerance 38 (34)
Other reasonsd 2 (2)
TKI, tyrosine kinase inhibitor.
a Proportions were calculated based on the total number of patients who switched from first-line TKI.
b Among these patients, 40% (45 of 113) had mutation detection done at any time before or after switching, and 19% 
(21 of 113) had mutation analysis done after the first switch; of those, 16 patients were switched due to resistance, 
and 5 patients were switched due to intolerance or other reasons.
c Group classified as resistance based on documented failure, resistance or lack/loss of efficacy, including patients 
with resistance and patients with resistance and intolerance. The intolerance group included patients who switched 
for intolerance only.
d Other reasons for switch were listed as they were recorded.




































































n First line Second line Third line Fourth line Fifth line Patients, n % (n=257)
Imatinib     112 43.6
Nilotinib     29 11.31 144
Dasatinib     3 1.2
Imatinib Nilotinib    37 14.4
Imatinib Dasatinib    5 1.9
Imatinib Bosutinib    5 1.9
Nilotinib Imatinib    6 2.3
Nilotinib Dasatinib    2 0.8
Nilotinib Bosutinib    3 1.2
2 59
Nilotinib Ponatinib    1 0.4
Imatinib Nilotinib Dasatinib   12 4.7
Imatinib Nilotinib Bosutinib   8 3.1
Imatinib Nilotinib Imatinib   1 0.4
Imatinib Dasatinib Bosutinib   3 1.2
Imatinib Dasatinib Nilotinib   2 0.8
Imatinib Dasatinib Ponatinib   2 0.8
Imatinib Dasatinib Imatinib   1 0.4
Imatinib Bosutinib Nilotinib   1 0.4
Nilotinib Imatinib Dasatinib   2 0.8
Nilotinib Imatinib Bosutinib   2 0.8
3 35
Nilotinib Imatinib Nilotinib   1 0.4
Imatinib Nilotinib Dasatinib Bosutinib  3 1.2
Imatinib Nilotinib Dasatinib Ponatinib  3 1.2
Imatinib Nilotinib Bosutinib Ponatinib  1 0.4
Imatinib Nilotinib Imatinib Nilotinib  1 0.4
Imatinib Nilotinib Dasatinib Imatinib  1 0.4
Imatinib Dasatinib Nilotinib Imatinib  1 0.4
Imatinib Bosutinib Dasatinib Imatinib  1 0.4
Nilotinib Imatinib Dasatinib Bosutinib  1 0.4
Nilotinib Imatinib Bosutinib Nilotinib  1 0.4
Nilotinib Dasatinib Bosutinib Ponatinib  1 0.4
Nilotinib Dasatinib Bosutinib Imatinib  1 0.4
4 16
Dasatinib Bosutinib Nilotinib Imatinib  1 0.4
Imatinib Dasatinib Bosutinib Ponatinib Imatinib 1 0.4
Imatinib Dasatinib Bosutinib Dasatinib Bosutinib 1 0.45 3
Imatinib Nilotinib Dasatinib Nilotinib Ponatinib 1 0.4
TKI, tyrosine kinase inhibitor.












































































Switched to 2L 
for resistance
(n=73)















50.2) 27.4 (1.2-51.4) 20.1 (2.8-54.1)
EMR at 3 months 
(±1 month) in 
patients with 
BCR-ABL1 at 3 
months, n (%)
59/70 (84) 10/10 (100) 49/60 (82) 38/45 (84) 39/47 (83) 20/23 (87)
MMR by 12 
months (±1 
month), n (%)
41/92 (45) 7/12 (58) 34/80 (43) 26/57 (46) 26/61 (43) 15/31 (48)
MMR at any 
time, n (%)
48/94 (51) 7/13 (54) 41/81 (51) 31/58 (53) 32/62 (52) 16/32 (50)
DMR at any time, 
n (%)
28/94 (30) 4/13 (31) 24/81 (30) 18/58 (31) 19/62 (31) 9/32 (28)
2G-TKI, second-generation tyrosine kinase inhibitor; 2L, second line; DMR, deep molecular response; ELN, 
European LeukemiaNet; EMR, early molecular response; IS, International Scale; MMR, major molecular response; 
RQ-PCR, real-time quantitative polymerase chain reaction. 
For EMR, patient was required to have RQ-PCR at 3 months (±1 month). 
Molecular response categories were not mutually exclusive; the same patient could appear in multiple response 
categories.
For MMR/DMR responses, denominator included only those patients with ≥1 RQ-PCR on second line (and by 12 
months [±1 month] on second line for the MMR by 12-month responses). 
a Follow-up period was months from second TKI until switch in patients who switched to third TKI or, in those 
who did not switch, to data collection or death. Molecular responses were assessed as early molecular response 
(EMR; BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any time, and DMR 
(BCR-ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, a window of 
±1 month was applied to ELN-defined time points; if multiple assessments were available within the window, the 
one closest to the time point was used.





































































1 Q252H Y Imatinib Nilotinib
2 E255V Y



















5 L384M Y Imatinib Nilotinib
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2L, second line; TKI, tyrosine kinase inhibitor.
a Among 113 patients who switched TKI, 40% (45 of 113) had mutation detection done at any time before or after 
switching;  21% (24 of 113) had mutation analysis done before the first switch, and of those, 20 patients were 
switched due to resistance (as documented in medical notes), and 4 patients were switched due to intolerance or 
other reasons. The mutation type was captured in 6 patients, as described here.  
b Resistance based on in vitro sensitivity (half maximal inhibitory concentration [IC50]) as described in ELN 2013 
(Baccarani et al 2013). 































































Supplementary Fig 1. TKI treatment pathways and molecular responses for patients with 
ELN-defined optimal, warning or failure responses while on second-line TKI
Both patients with a warning response switched after a warning at a single ELN-defined milestone. MMR or DMR 
response may have been observed at any time; duration of follow up varied; patient may have had ≥1 subsequent 
TKI switch. DMR, deep molecular response; ELN, European LeukemiaNet; MMR, major molecular response; TKI, 
tyrosine kinase inhibitor.
































































Supplementary Table I. Reasons for choice of first-line TKI recorded for ≥2% of all 
patients








Known reasonsb 113 (44%) 92 (45) 21 (39)
Clinician preference 26 (10) 18 (9) 8 (15)
Standard first-line choice 20 (8) 17 (8) 3 (6)
Good results expected 17 (7) 15 (7) 2 (4)
Ease of administration 9 (4) 9 (4) 0
Ineligibility for clinical trial/no trial 
available
9 (4) 9 (4) 0
Cardiovascular comorbidities 9 (4) 9 (4) 0
Low risk 7 (3) 7 (3) 0
Tolerability/side effect profile 7 (3) 6 (3) 1 (2)
Perceived as better option 
compared with others
7 (3) 6 (3) 1 (2)
Patient choice 7 (3) 5 (2) 2 (4)
Local or network guidance 7 (3) 7 (3) 0
Smoker 6 (2) 6 (3) 0
Patient age 3 (1) 3 (1) 0
Diabetes 3 (1) 3 (1) 0
High Sokal risk score 3 (1) 1 (<1) 2 (4)
Renal comorbidities 2 (1) 2 (1) 0
Started treatment in another 
country (and moved to United 
Kingdom)
2 (1) 0 2 (4)
Intermediate Sokal risk 1 (<1) 0 1 (2)
Low QRISK 1 (<1) 0 1 (2)
Reasons unknown 144 (56) 111 (55) 33 (61)
2G-TKI, second-generation tyrosine kinase inhibitor.
a Percentages were calculated out of total number of patients in each column.
b Some patients had multiple reasons recorded.










































































Documenteda 74 (29) 62 (31) 12 (22) 11 (22)
Normal
(SBP <120 mm Hg and 
DBP <80 mm Hg)
14 (19) 11 (18) 3 (25) 3 (27)
Elevated
(SBP 120-129 mm Hg and 
DBP <80 mm Hg)
15 (20) 13 (21) 2 (17) 1 (9)
Stage 1 hypertension
(SBP 130-139 mm Hg or 
DBP 80-89 mm Hg)
12 (16) 8 (13) 4 (33) 4 (36)
Stage 2 hypertension
(SBP ≥140 mm Hg or DBP 
≥90 mm Hg)
30 (41) 27 (44) 3 (25) 3 (27)
Hypertensive crisis
(SBP >180 mm Hg and/or 
DBP >120 mm Hg)
3 (4) 3 (5) 0 0
Not documented 182 (71) 140 (69) 42 (78) 39 (78)
Not known whether 
documented 1 (<1)
b 1 (<1)b 0 0
2G-TKI, second-generation tyrosine kinase inhibitor; DBP, diastolic blood pressure; SBP, systolic blood pressure.
a Proportion of patients in each blood pressure category is calculated out of the number of patients with documented 
blood pressure.
b One patient was transferred from another hospital prior to TKI treatment; it was unclear if this patient’s blood 
pressure had been documented prior to TKI treatment.































































Supplementary Table III. Reasons for switch from first-line TKI
n (%)a
Patients who switched from first-line TKI
(n=113)b
Resistancec 73 (65)
Intolerance or other reasons 40 (35)
Intolerance 38 (34)
Other reasonsd 2 (2)
TKI, tyrosine kinase inhibitor.
a Proportions were calculated based on the total number of patients who switched from first-line TKI.
b Among these patients, 40% (45 of 113) had mutation detection done at any time before or after switching, and 19% 
(21 of 113) had mutation analysis done after the first switch; of those, 16 patients were switched due to resistance, 
and 5 patients were switched due to intolerance or other reasons.
c Group classified as resistance based on documented failure, resistance or lack/loss of efficacy, including patients 
with resistance and patients with resistance and intolerance. The intolerance group included patients who switched 
for intolerance only.
d Other reasons for switch were listed as they were recorded.




































































n First line Second line Third line Fourth line Fifth line Patients, n % (n=257)
Imatinib     112 43.6
Nilotinib     29 11.31 144
Dasatinib     3 1.2
Imatinib Nilotinib    37 14.4
Imatinib Dasatinib    5 1.9
Imatinib Bosutinib    5 1.9
Nilotinib Imatinib    6 2.3
Nilotinib Dasatinib    2 0.8
Nilotinib Bosutinib    3 1.2
2 59
Nilotinib Ponatinib    1 0.4
Imatinib Nilotinib Dasatinib   12 4.7
Imatinib Nilotinib Bosutinib   8 3.1
Imatinib Nilotinib Imatinib   1 0.4
Imatinib Dasatinib Bosutinib   3 1.2
Imatinib Dasatinib Nilotinib   2 0.8
Imatinib Dasatinib Ponatinib   2 0.8
Imatinib Dasatinib Imatinib   1 0.4
Imatinib Bosutinib Nilotinib   1 0.4
Nilotinib Imatinib Dasatinib   2 0.8
Nilotinib Imatinib Bosutinib   2 0.8
3 35
Nilotinib Imatinib Nilotinib   1 0.4
Imatinib Nilotinib Dasatinib Bosutinib  3 1.2
Imatinib Nilotinib Dasatinib Ponatinib  3 1.2
Imatinib Nilotinib Bosutinib Ponatinib  1 0.4
Imatinib Nilotinib Imatinib Nilotinib  1 0.4
Imatinib Nilotinib Dasatinib Imatinib  1 0.4
Imatinib Dasatinib Nilotinib Imatinib  1 0.4
Imatinib Bosutinib Dasatinib Imatinib  1 0.4
Nilotinib Imatinib Dasatinib Bosutinib  1 0.4
Nilotinib Imatinib Bosutinib Nilotinib  1 0.4
Nilotinib Dasatinib Bosutinib Ponatinib  1 0.4
Nilotinib Dasatinib Bosutinib Imatinib  1 0.4
4 16
Dasatinib Bosutinib Nilotinib Imatinib  1 0.4
Imatinib Dasatinib Bosutinib Ponatinib Imatinib 1 0.4
Imatinib Dasatinib Bosutinib Dasatinib Bosutinib 1 0.45 3
Imatinib Nilotinib Dasatinib Nilotinib Ponatinib 1 0.4
TKI, tyrosine kinase inhibitor.












































































Switched to 2L 
for resistance
(n=73)















50.2) 27.4 (1.2-51.4) 20.1 (2.8-54.1)
EMR at 3 months 
(±1 month) in 
patients with 
BCR-ABL1 at 3 
months, n (%)
59/70 (84) 10/10 (100) 49/60 (82) 38/45 (84) 39/47 (83) 20/23 (87)
MMR by 12 
months (±1 
month), n (%)
41/92 (45) 7/12 (58) 34/80 (43) 26/57 (46) 26/61 (43) 15/31 (48)
MMR at any 
time, n (%)
48/94 (51) 7/13 (54) 41/81 (51) 31/58 (53) 32/62 (52) 16/32 (50)
DMR at any time, 
n (%)
28/94 (30) 4/13 (31) 24/81 (30) 18/58 (31) 19/62 (31) 9/32 (28)
2G-TKI, second-generation tyrosine kinase inhibitor; 2L, second line; DMR, deep molecular response; ELN, 
European LeukemiaNet; EMR, early molecular response; IS, International Scale; MMR, major molecular response; 
RQ-PCR, real-time quantitative polymerase chain reaction. 
For EMR, patient was required to have RQ-PCR at 3 months (±1 month). 
Molecular response categories were not mutually exclusive; the same patient could appear in multiple response 
categories.
For MMR/DMR responses, denominator included only those patients with ≥1 RQ-PCR on second line (and by 12 
months [±1 month] on second line for the MMR by 12-month responses). 
a Follow-up period was months from second TKI until switch in patients who switched to third TKI or, in those 
who did not switch, to data collection or death. Molecular responses were assessed as early molecular response 
(EMR; BCR-ABL1IS ≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any time, and DMR 
(BCR-ABL1IS ≤0.01%) at any time. To account for variations in real-world appointment scheduling, a window of 
±1 month was applied to ELN-defined time points; if multiple assessments were available within the window, the 
one closest to the time point was used.
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2L, second line; TKI, tyrosine kinase inhibitor.
a Among 113 patients who switched TKI, 40% (45 of 113) had mutation detection done at any time before or after 
switching;  21% (24 of 113) had mutation analysis done before the first switch, and of those, 20 patients were 
switched due to resistance (as documented in medical notes), and 4 patients were switched due to intolerance or 
other reasons. The mutation type was captured in 6 patients, as described here.  
b Resistance based on in vitro sensitivity (half maximal inhibitory concentration [IC50]) as described in ELN 2013 
(Baccarani et al 2013). 






























































































































Supplementary Fig 1. TKI treatment pathways and molecular responses for patients with 
ELN-defined optimal, warning or failure responses while on second-line TKI
Both patients with a warning response switched after a warning at a single ELN-defined milestone. MMR or DMR 
response may have been observed at any time; duration of follow up varied; patient may have had ≥1 subsequent 
TKI switch. DMR, deep molecular response; ELN, European LeukemiaNet; MMR, major molecular response; TKI, 
tyrosine kinase inhibitor.






























































Reviewer 1 major comments:
1. It is stated that patients receiving a 2G-TKI were younger than those receiving imatinib but what was 
median ages and range. Is there a statistical analysis attached to this observation. 
Author Response: We have added clarification to the Results (page 7, lines 145-147 of the tracked 
changes version of our resubmission), as follows: Patients receiving a first-line 2G-TKI were younger 
(median, 46 years [95% CI, 41-53 years]) than those receiving first-line imatinib (median, 55 years 
[95% CI, 52-59 years]; Mann-Whitney U test, P = 0.0128).
2a. For first-line TKI therapy category, what was the definition and split of patients that were defined as 
failure? 
Author Response: We would like to draw the reviewer’s attention to lines 184-185 on page 9, which 
provide the breakdown of reasons for switch, as follows: Reasons for the first switch were resistance 
in 73 (65%), intolerance in 38 (34%) and other reasons in 2 (2%) (Supplementary Table III). These 
reasons for switch were captured from patient notes, where resistance included any recorded failure, 
resistance, loss of response, lack of efficacy or loss of efficacy. This resistant group also included 
patients for whom both lack of efficacy and intolerance were documented as reasons for the switch. 
Intolerance was used to describe patients who switched purely for intolerance reasons (not lack of 
efficacy).
We have added further clarification to footnote c of Supplementary Table III (page 3 of the 
supplemental document), as follows: Group classified as resistance based on documented failure, 
resistance or lack/loss of efficacy, including patients with resistance and patients with resistance and 
intolerance. The intolerance group included patients who switched for intolerance only.
We have further clarified in the text that objectives included describing recorded reasons for 
stopping/changing TKIs (page 6, line 116).
For the ELN-defined milestones, we have further clarified the text (page 6, lines 126-127), as follows: 
For comparison with ELN, where data were available, responses were categorised as optimal, warning 
or failure according to ELN 2013 recommendations (Baccarani et al, 2013).
The ELN-defined milestone of failure in first-line therapy (Figure 2) is defined as per ELN at 3, 6 and 12 
months, within a 1-month window. We added clarification to footnote a of Figure 2 (pages 34-35, lines 
638-641), as follows: To account for variations in real-world appointment scheduling, a window of ±1 
month was applied to ELN-defined time points (3, 6 and 12 months). In patients with multiple test 
results available, any patient with a failure response to first-line TKI at an ELN milestone (regardless of 
other responses achieved at earlier milestones) was classified as having a failure response.
2b. What time points were used? 
Author Response: ELN timepoints of 3, 6 and 12 months were used. We added this information to 
footnote a in Figure 2 for clarification (page 34, line 639). 
2c. Were any failure time points pre-empted by ELN-defined warnings? 






























































Author Response: To clarify the ELN-failure group, we have added footnote c to Figure 2 (page 35, 
lines 657-659), as follows: Of 48 patients with ELN-defined failure responses, 39 were treated with 
imatinib as first-line therapy and 9 with a 2G-TKI; 38 patients (79%) also had an ELN-defined warning 
at a prior ELN time point (with either a molecular or cytogenetic test).
2d. Given the large proportion of patients without an evaluable molecular or cytogenetic test in the first 
year of therapy, how was this absent data managed.
Author Response: We would like to draw the reviewer’s attention to the last two sentences of 
footnote a of Figure 2 (page 35, lines 644-644), which state the following: Patients without 
assessments at any ELN milestone could not be categorized. Thirty-four patients had no evaluable test 
at any ELN milestone by either molecular or cytogenetic test.
3. What was the definition of resistance in patients who switched TKI as the numbers who had failure to 
first-line TKI do not match the number of patients with resistance.  
Author Response: We thank the reviewer for this comment. It is important here to distinguish 
between ELN-defined failure and switch of TKI due to resistance, as documented in the patient record. 
It is one of the interesting findings of our work that the two do not correlate, i.e., some patients with 
ELN-defined failure did not switch TKI, while some patients switched due to “resistance” (as 
documented in the patient record) even though the ELN criteria for treatment failure were not met. 
We have tried to clarify this important distinction in the text as described below.
We would like to draw the reviewer’s attention to lines 184-185 on page 9, which provide the 
breakdown of reasons for switch, as follows: Reasons for the first switch were resistance in 73 (65%), 
intolerance in 38 (34%) and other reasons in 2 (2%) (Supplementary Table III). These reasons for switch 
were captured from patient notes, where resistance included any recorded failure, resistance, loss of 
response, lack of efficacy or loss of efficacy. This resistant group also included patients for whom both 
lack of efficacy and intolerance were documented as reason for the switch. Intolerance was used to 
describe patients who switched purely for intolerance reasons (not lack of efficacy).
We have added further clarification to footnote c of Supplementary Table III (page 3 of the 
supplemental document), as follows: Group classified as resistance based on documented failure, 
resistance or lack/loss of efficacy, including patients with resistance and patients with resistance and 
intolerance. The intolerance group included patients who switched for intolerance only.
We have further clarified in the text that objectives included describing recorded reasons for 
stopping/changing TKIs (page 6, line 116).
For the ELN-defined milestones, we have further clarified the text (page 6, lines 126-127), as follows: 
For comparison with ELN, where data were available, responses were categorised as optimal, warning 
or failure according to ELN 2013 recommendations (Baccarani et al, 2013).
The ELN-defined milestone of failure in first-line therapy (Figure 2) is defined as per ELN at 3, 6 and 12 
months, within a 1-month window. We added clarification to footnote a of Figure 2 (pages 34-35, lines 
638-641), as follows: To account for variations in real-world appointment scheduling, a window of ±1 
month was applied to ELN-defined time points (3, 6 and 12 months). In patients with multiple test 






























































results available, any patient with a failure response to first-line TKI at an ELN milestone (regardless of 
other responses achieved at earlier milestones) was classified as having a failure response.
To further clarify the ELN-failure group, we have added footnote c to Figure 2 (page 35, lines 657-659), 
as follows: Of 48 patients with ELN-defined failure responses, 39 were treated with imatinib as first-
line therapy and 9 with a 2G-TKI; 38 patients (79%) also had an ELN-defined warning at a prior ELN 
time point (with either a molecular or cytogenetic test).
4. For patients with intolerance, was there any data on dose modification/reduction prior to
switch? How were these graded? Minor adverse events or serious adverse events such as pleural 
effusions, or cardiovascular events? 
Author Response: We would like to clarify that adverse events were not collected as per the protocol 
in this study (page 6, lines 117-118). Therefore, although dose modifications were captured, allowing 
comparison between imatinib and 2G-TKIs, the reasons for dose modifications were not captured. We 
would like to draw the reviewer’s attention to the following text on lines 173-175 (page 8) for 
clarification of level of reduction/modifications in first line: For patients receiving imatinib or nilotinib, 
respective median starting doses were 400 or 600 mg/day; 24/203 (12%) and 8/50 (16%) had dose 
reductions, while 14% and 12% had dose interruptions.
5. In Table 1 and 2, >90% of 2G-TKI patients were on nilotinib. Does it serve a purpose to split patients in 
nilotinib treated at all or is this redundant. 
Author Response: We would like to highlight that choice of 2G-TKI is of specific interest based on 
baseline comorbidities, as dasatinib and nilotinib have distinct profiles.
6a. Table 4 needs to be reworked. Is the overall responses and first-line TKI responses not reporting the 
same thing? How are the denominators different if they are both looking at first-line TKIs?
Author Response: We would like to clarify that the analysis of overall response is an intention-to-treat 
type of analysis, which is based on first-line TKI but also includes data from later-line TKI treatment in 
patients who switched from their first-line TKI; in contrast, the analysis of first-line TKI response 
reflects responses observed on first-line TKI only. 
We have added clarification to footnote c of Table IV (page 31, lines 601-602), which is now worded as 
follows: The columns for overall response reported the duration of follow-up for all TKI therapies, 
including later-line TKIs in patients who switched from their first-line TKI (from start of first-line TKI to 
most recent data collection, akin to an intention-to-treat analysis). The columns for first-line TKI 
therapy reported the duration of follow-up for only first-line TKI therapy (from start of first-line TKI to 
most recent data collection or death in patients who continued receiving first-line TKI or to end of first-
line TKI for patients who switched to a second-line TKI). 
6b. What is the purpose of differentiating nilotinib patients from dasatinib patients when >90% are 
nilotinib treated. 
Author Response: This demonstrates that observed outcome data were not skewed by the 4 
dasatinib-treated patients and provides consistency in groupings from baseline (please see our 
response to Comment 5 above). 






























































7a. Table 5 needs to be reworked. Is EMR in these patients assessing 3-month BCR-ABL1 levels after 
switching to the second-line agent or at 3 months of first-line TKI?  
Author Response: Table V is a summary of molecular responses after switching to second-line TKI 
therapy. To provide clarity, we have edited footnote a of Table V (page 32, lines 611-615), which now 
reads as follows: Molecular responses after switch to second TKI were assessed as EMR (BCR-ABL1IS 
≤10% at 3 months), MMR (BCR-ABL1IS ≤0.1%) by 12 months, MMR at any time and DMR (BCR-ABL1IS 
≤0.01%) at any time. 
7b. Row 4 and 5 are confusing. 
Author Response: To simplify Table V (page 32), we have removed row 4 (i.e., EMR at 3 months [±1 
month] in patients with BCR-ABL1 at 3 months, n [%]), as this is not needed in addition to row 5.
Reviewer 1 minor comment:
1. In patients that had kinase domain mutations assessed, how many had actionable mutations?
Author Response: As detailed in the table below, all mutations recorded were clinically actionable. 
We have added this information as Supplementary Table VI (page 6 of supplemental document) 
Supplementary Table VI. Summary of documented mutationsa
Patient Details Actionable mutation 
(Y/N)
Resistanceb 2L TKI
1 Q252H Y Imatinib Nilotinib
2 E255V Y Imatinib and to lesser extent 
nilotinib, bosutinib
Dasatinib
3 T315I Y All TKIs except ponatinib Ponatinib
4 E255K
F359C
Y Imatinib and to lesser extent 
nilotinib, bosutinib
Dasatinib
5 L384M Y Imatinib Nilotinib
6 E255V Y Imatinib and to lesser extent 
nilotinib, bosutinib
Dasatinib
a Among 113 patients who switched TKI, 40% (45 of 113) had mutation detection done at any time before or after switching;  
21% (24 of 113) had mutation analysis done before the first switch, and of those, 20 patients were switched due to resistance 
(as documented in medical notes), and 4 patients were switched due to intolerance or other reasons. The mutation type was 
captured in 6 patients as described here.  
b Resistance based on in vitro sensitivity (half maximal inhibitory concentration [IC50]) as described in ELN 2013 (Baccarani et al 
2013). 
    
Editor’s comments: 
1. Please let me have your rebuttal and an amended manuscript as soon as possible so that I can make a 
decision on publication.  Please ensure that one copy clearly highlights all changes made (ie in bold).
Author Response: We have submitted a version of the manuscript with tracked changes in addition to 
providing a clean copy.






























































2. You must list the pages and lines which have been amended.
Author Response: We have included the relevant page and line numbers in our responses to each 
reviewer comment. 
3. Please ensure that the correct gene symbol, as defined by the HGNC http://www.gene.ucl.ac.uk/cgi-
bin/nomenclature/searchgenes.pl), is used for all genes mentioned in your paper.
Author Response: We have used this format for all genes mentioned in the manuscript.
4. Please quote your manuscript number and email address on all correspondence.
Author Response: We have included both the manuscript number and email address at the top of this 
letter.
5. Please submit an electronic version of each figure in either TIFF or EPS format, at a recommended 
resolution of 600 dpi, according to the information given at 
http://www.blackwellpublishing.com/authors/ digill.asp
Author Response: We have ensured that the submitted figures are in the correct format and 
resolution.
6. If you have not already done so, please could you provide five suitable keywords, and a short title of 
up to 60 characters and spaces.
Author Response: We have included a running title on the title page (page 1, line 5) and 5 key words 
below the abstract (page 3, lines 61-62).
7. Please also make sure your manuscript is in the correct format for this journal; failure to do so may 
DELAY the processing of your paper. BJH uses the HARVARD system of referencing: citations in the text 
take the form of author names and dates (e.g. Smith et al. 1990).).  
Author Response: We have followed this format for the manuscript.
8. All references should be brought together at the end of the paper in ALPHABETICAL ORDER, with all 
AUTHORS, titles and TITLES OF JOURNALS spelt out in full, with both first and last page numbers given. 
REFERENCES MUST NOT BE NUMBERED.
Author Response: All references have been placed at the end of the manuscript in alphabetical order 
and not numbered. Titles of journals are spelled out, and first and last page numbers are included.
9. We also need full postal address, phone and fax numbers.
Author Response: We have provided full postal address and phone and fax numbers as requested.
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